var title_f13_51_14128="Pleural lymphatic lacunae";
var content_f13_51_14128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pleural lymphatic lacunae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Drainage of pleural lymphatics. Each pleural lymphatic vessel joins others, forming a lake or lacuna (L). From the lacunae, collecting lymphatics join intercostal trunk lymphatics which travel to the parasternal and periaortic lymph nodes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kurt H Albertine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14128=[""].join("\n");
var outline_f13_51_14128=null;
var title_f13_51_14129="Labaret stud";
var content_f13_51_14129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Labaret stud",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of R Michelle Schmidt, MD and Myrna L Armstrong, EdD, RN, FAAN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14129=[""].join("\n");
var outline_f13_51_14129=null;
var title_f13_51_14130="Disseminated granuloma annulare leg PI";
var content_f13_51_14130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Granuloma annulare on the leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows generalized granuloma annulare. Each circle- and arc-shaped area has red, raised edges and a skin-colored center.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14130=[""].join("\n");
var outline_f13_51_14130=null;
var title_f13_51_14131="Erythema multiforme genital";
var content_f13_51_14131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions are present on the penis of this patient with erythema multiforme. A target-like lesion is present on the distal glans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14131=[""].join("\n");
var outline_f13_51_14131=null;
var title_f13_51_14132="RimabotulinumtoxinB (botulinum toxin type B, Myobloc): Pediatric drug information";
var content_f13_51_14132=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   RimabotulinumtoxinB (botulinum toxin type B, Myobloc): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"    see \"RimabotulinumtoxinB (botulinum toxin type B, Myobloc): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/58/14244?source=see_link\">",
"    see \"RimabotulinumtoxinB (botulinum toxin type B, Myobloc): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9606304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Myobloc&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Muscle Contracture, Treatment",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"      see \"RimabotulinumtoxinB (botulinum toxin type B, Myobloc): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Adults: 2500-5000 units divided among affected muscles; patients without a prior history of tolerating botulinum toxin injections should receive a lower initial dose; subsequent doses should be individualized related to the patient's response; doses up to 10,000 units have been used",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myobloc&reg;: 5000 units/mL (0.5 mL, 1 mL, 2 mL) [contains albumin (human)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8104024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176361.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176361.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: For I.M. administration only by individuals understanding the relevant neuromuscular anatomy and any alterations to the anatomy due to prior surgical procedures and standard electromyographic techniques; solution may be diluted with NS prior to administration",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F142033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with any other medicines.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store solution in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); stable for 4 hours at room temperature after dilution with NS",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cervical dystonia (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7728707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Botulinum products are not interchangeable; potency differences may exist between the products.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F142032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, peripheral edema, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, confusion, dizziness, fever, headache, hyperesthesia, malaise, migraine, pain, somnolence, tremor, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, dysphagia, glossitis, nausea, stomatitis, taste perversion, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis, urinary tract infection, vaginal moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Serum neutralizing activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain, hernia, myasthenia, neck pain, torticollis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, vision abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pneumonia, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abscess, allergic reaction, antibody formation, cyst, flu-like syndrome, infection, neoplasm, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Constipation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to botulinum toxin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with peripheral motor neuropathic diseases (eg, amyotrophic lateral sclerosis or motor neuropathy) or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) as these patients may be at increased risk for development of significant systemic side effects including severe dysphagia and respiratory compromise; use cautiously if there is inflammation present at the proposed injection site or when excessive weakness or atrophy is present in the target muscles",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of rimabotulinumtoxinB should be reserved for healthcare providers familiar and experienced in the assessment and management of patients with cervical dystonia",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The U.S. Food and Drug Administration (FDA) and Health Canada have issued respective early communications to healthcare professionals alerting them of serious adverse events (including fatalities) in association with the use of onabotulinumtoxinA  (Botox&reg;, Botox&reg; Cosmetic) and rimabotulinumtoxinB (Myobloc&reg;). Events reported are suggestive of botulism, indicating systemic spread of the botulinum toxin beyond the site of injection. Reactions were observed in both adult and pediatric patients treated for a variety of conditions with varying doses. However, the most serious outcomes, including respiratory failure and death, were associated with the use in children for cerebral palsy limb spasticity. The FDA has evaluated postmarketing cases and now reports that systemic and potentially fatal toxicity may result from local injection of the botulinum toxins in the treatment of other underlying conditions such as cerebral palsy associated with limb spasticity. Monitor patients closely for signs/symptoms of systemic toxic effects (possibly occurring 1 day to several weeks after treatment) and instruct patients to seek immediate medical attention with worsening symptoms or dysphagia, dyspnea, muscle weakness, or difficulty speaking.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the adverse neuromuscular effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: May enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: May enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F141993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (manufacturer) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F142003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Based on limited case reports using onabotulinumtoxinA, adverse fetal effects have not been observed with inadvertent administration during pregnancy. It is currently recommended to ensure adequate contraception in women of childbearing years.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor patients closely for signs/symptoms of systemic toxic effects (possibly occurring 1 day to several weeks after treatment)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) which evaluates severity, disability, and pain",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     RimabotulinumtoxinB (formerly known as botulinum B toxin) is one of seven neurotoxins produced by",
"     <i>",
"      Clostridium botulinum",
"     </i>",
"     , a spore-forming anaerobic bacillus; it blocks neuromuscular conduction by binding to receptor sites on motor nerve terminals, entering the nerve terminals and inhibiting the release of acetylcholine. RimabotulinumtoxinB also cleaves synaptic vesicle associated membrane protein (VAMP), a component of the protein complex involved in neurotransmitter release. When injected intramuscularly at therapeutic doses, it produces a localized chemical denervation muscle paralysis. When the muscle is chemically denervated, it atrophies and may develop extrajunctional acetylcholine receptors. There is evidence that the nerve can sprout and reinnervate the muscle, with the weakness being reversible.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration of paralysis: 12-16 weeks",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/58/14244?source=see_link\">",
"      see \"RimabotulinumtoxinB (botulinum toxin type B, Myobloc): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Botulinum Toxin,&rdquo;",
"      <i>",
"       NIH Consens Statement",
"      </i>",
"      , 1990, 12-14, 8(8):1-20.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Figgitt DP and Noble S, &ldquo;Botulinum Toxin B: A Review of Its Therapeutic Potential in the Management of Cervical Dystonia,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2002, 62(4):705-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14132/abstract-text/11893235/pubmed\" id=\"11893235\" target=\"_blank\">",
"        11893235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12898 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14132=[""].join("\n");
var outline_f13_51_14132=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606304\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142011\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056931\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056924\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141996\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141983\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8104024\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056934\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142033\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056927\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056933\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7728707\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142032\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056937\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056923\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056922\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300001\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141991\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141993\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142003\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056930\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056921\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056936\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056929\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12898|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=related_link\">",
"      RimabotulinumtoxinB (botulinum toxin type B, Myobloc): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/58/14244?source=related_link\">",
"      RimabotulinumtoxinB (botulinum toxin type B, Myobloc): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_51_14133="CA-MRSA virulence factors";
var content_f13_51_14133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Multiple factors probably contribute to the enhanced virulence of community acquired-MRSA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 494px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Virulence determinants include phenol-soluble modulins, alpha-hemolysin, and several of the other determinants shown. The expression of these factors is likely to be under regulatory control. Other factors, such as the host response and factors that facilitate transmission, have yet to be characterized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Lowy FD. Secrets of a superbug. Nat Med 2007; 13:1418. Copyright &copy; 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14133=[""].join("\n");
var outline_f13_51_14133=null;
var title_f13_51_14134="Renal and perinephric abscess";
var content_f13_51_14134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal and perinephric abscess",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/51/14134/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14134/contributors\">",
"     Alain Meyrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/51/14134/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14134/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/51/14134/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14134/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/51/14134/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal and perinephric abscess are complications of urinary tract infection that usually occur in the setting of ascending infection with obstructed pyelonephritis (usually due to gram-negative enteric bacilli or polymicrobial infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The major predisposing conditions for renal and perinephric suppuration are diabetes mellitus and renal stones. However, they also occur in the setting of bacteremia with hematogenous seeding, usually due to Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Infections in these sites are sometimes referred to as renal (or kidney) carbuncles and perirenal abscesses, respectively.",
"   </p>",
"   <p>",
"    Renal abscess occurs more frequently than perinephric abscess. Both start with tissue necrosis (lobar necrosis in renal abscess; perirenal fat necrosis in perinephric abscess). Renal abscess forms a walled-off cavity; perinephric abscess consists of a more diffuse liquefaction.",
"   </p>",
"   <p>",
"    Predisposing factors include diabetes mellitus and urinary tract abnormality (such as renal stone--especially large staghorn stones, vesicoureteral reflux, neurogenic bladder, obstructive tumor, benign cyst, or polycystic kidney disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis and management of renal and perinephric abscesses will be reviewed here. Pyelonephritis, emphysematous pyelonephritis and xanthogranulomatous pyelonephritis are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=see_link\">",
"     \"Emphysematous urinary tract infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16804?source=see_link\">",
"     \"Xanthogranulomatous pyelonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of renal and perinephric abscess are similar to those of a severe, acute pyelonephritis. These include fever, flank pain, abdominal pain, dysuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequency. A palpable mass may or may not be present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/8\">",
"     8",
"    </a>",
"    ]. In the setting of perirenal suppuration, the overlying skin may demonstrate an inflammatory reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/9\">",
"     9",
"    </a>",
"    ]. The diagnosis should be considered in patients with signs and symptoms of acute renal infection that fail to improve after five days of appropriate antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal or perinephric abscess may also present insidiously with few or no symptoms, particularly in the elderly and in individuals with autonomic neuropathy (as in the setting of diabetes or chronic alcoholism) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ]. In addition, renal abscess or multiple miliary abscesses are a classic complication of Staphylococcus aureus bacteremia that may present up to eight weeks after initial skin or soft tissue infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/3,5,14\">",
"     3,5,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood and urine cultures should be collected at the time of presentation, along with urinalysis and routine blood work. Urinalysis usually demonstrates abundant pyuria and moderate proteinuria in the setting of abscess that develops following progression of acute pyelonephritis. In contrast, urine studies may be normal if renal or perinephric abscess develops as result of hematogenous spread and does not communicate with the collecting system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/7,14\">",
"     7,14",
"    </a>",
"    ]. Leukocytosis is frequently observed in the setting of renal and perinephric abscess, although it is not a specific finding. Elevated erythrocyte sedimentation rate (ESR) and CRP (C-reactive protein) are markers of deep seated infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiography should be used for definitive diagnosis of renal or perinephric abscess; the most useful modalities are ultrasonography and computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/4\">",
"     4",
"    </a>",
"    ]. Nuclear imaging and MRI have a limited utility [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain radiography is not used as a diagnostic test for renal and perinephric abscess but occasionally reveals signs suggestive of these diagnoses when done for other purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/17\">",
"     17",
"    </a>",
"    ]. Abdominal films may demonstrate an abdominal mass, an enlarged kidney with indistinct outlines, a loss of psoas margin, a radioopaque calculus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a poorly defined renal shadow. Chest radiography may demonstrate a pleural effusion, ipsilateral pneumonia, atelectasis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevated hemidiaphragm.",
"   </p>",
"   <p>",
"    Computed tomography (CT) with contrast medium enhancement is preferred for evaluation of renal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perinephric abscesses. While ultrasound can also be used to make the diagnosis, CT is better for identifying other abnormalities that may present with similar symptoms.",
"   </p>",
"   <p>",
"    Renal abscesses arising as a consequence of focal suppuration in the setting of acute pyelonephritis can occur in the cortex, medulla, or both; in contrast, renal abscesses due to hematogenous spread are usually located in the cortex.",
"   </p>",
"   <p>",
"    Ultrasonography typically demonstrates a thick-walled cavity filled with fluid in the setting of renal abscess (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63479 \" href=\"UTD.htm?6/29/6609\">",
"     image 1",
"    </a>",
"    ). Pus may be difficult to distinguish from sterile urine or blood, and echoes due to renal tissue debris can be difficult to distinguish from necrosis within a necrotic renal cancer. Ultrasonography is strongly suggestive of suppuration when it shows a horizontal separation between an upper level of low-density fluid (urine) and an underlying level of more dense fluid (pus). Films taken one or two hours following injection of contrast medium may show an enhanced rim around the abscess cavity.",
"   </p>",
"   <p>",
"    Perinephric abscesses are usually confined to the perinephric space by Gerota's fascia but may extend to the retroperitoneal structures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rupture into the collecting system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/7,18\">",
"     7,18",
"    </a>",
"    ]. An abscess in the perinephric space may also penetrate into the flank muscles or into the psoas muscle; it may extend caudally between the diverging layers of Gerota's fascia and present as an abscess in the groin or paravesical area. Less commonly, there may be extension into the peritoneal cavity. Cephalad extension may lead to formation of a subphrenic abscess, penetration of the diaphragm and empyema formation, lung abscess, or nephrobronchial fistula. Rupture into the colon occurs infrequently [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT findings may include thickening of Gerota's fascia, renal enlargement, parenchymatous inflammation, decreased attenuation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lobar necrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60754 \" href=\"UTD.htm?35/14/36079\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75530 \" href=\"UTD.htm?42/11/43184\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51469 \" href=\"UTD.htm?1/48/1793\">",
"     image 4",
"    </a>",
"    ). Fluid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gas may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal and perinephric abscess should be distinguished from other entities, including acute lobar nephronia, acute pyelonephritis complicated by papillary necrosis, emphysematous pyelonephritis, malakoplakia, and renal cell carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=see_link&amp;anchor=H5#H5\">",
"     \"Emphysematous urinary tract infections\", section on 'Emphysematous pyelonephritis and pyelitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malakoplakia is a rare granulomatous inflammatory disease associated with E coli infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/23\">",
"     23",
"    </a>",
"    ]. It usually affects the bladder; the kidney is the primary site of involvement in about 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/24\">",
"     24",
"    </a>",
"    ]. The diagnosis is made based on histological findings including PAS-positive Michaelis-Gutmann (MG) bodies, which are thought to result from inadequate intracellular killing of phagocytosed bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/25\">",
"     25",
"    </a>",
"    ]. Therapy should consist of antimicrobial therapy tailored to culture and sensitivity data.",
"   </p>",
"   <p>",
"    Acute lobar nephronia (also known as acute focal bacterial nephritis or acute focal pyelonephritis) is an acute, nonsuppurative renal infection that represents a variant of acute pyelonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/12,26,27\">",
"     12,26,27",
"    </a>",
"    ]. There is disagreement in the literature (among radiologists, pathologists and clinicians) regarding the nomenclature used to describe acute lobar nephronia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/28\">",
"     28",
"    </a>",
"    ]. Although the term was initially used to denote a localized process observed on CT in patients with acute bacterial kidney infection (the term was coined by analogy to \"acute lobar pneumonia\"), there is no doubt that &ldquo;acute lobar nephronia&rdquo; is not a distinct entity but simply part of the continuum of bacterial renal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute lobar nephronia may be visualized radiographically. Ultrasonography usually demonstrates a focal mass of hyper-, iso- or hypoechogenicity compared with the renal parenchymal tissue (rather than a walled off cavity as seen with intrarenal abscess). Computed tomography (CT) typically demonstrates a wedge-shaped poorly defined area of decreased density (rather than a well defined walled-off cavity as seen with intrarenal abscess). Management consists of antibiotic therapy (usually 2 to 3 weeks) in the absence of drainage, despite its focal nature.",
"   </p>",
"   <p>",
"    Renal abscess, malakoplakia and acute lobar nephronia may be difficult to distinguish radiographically from renal cell carcinoma; this entity is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to management of renal and perinephric abscess includes antimicrobial therapy in conjunction with drainage (when warranted) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/1,29\">",
"     1,29",
"    </a>",
"    ]. In addition, urologic obstruction should be relieved promptly if present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Drainage",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Renal abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with renal abscesses &gt;5 cm should be managed with percutaneous drainage in conjunction with antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/3,4,30-32\">",
"     3,4,30-32",
"    </a>",
"    ]. For renal abscesses &lt;5 cm in diameter, antimicrobial therapy (in the absence of drainage) is appropriate initial management [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/3,32,33\">",
"     3,32,33",
"    </a>",
"    ]. These lesions frequently respond well to prolonged antibiotic treatment, and radiographic localization for drainage can be difficult. If clinical symptoms and radiographic findings persist after several days of therapy, percutaneous drainage of abscesses &lt;5 cm should be considered if technically possible [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/3,4,31,32\">",
"     3,4,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success of this approach was illustrated in a retrospective review of 52 patients with renal abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/32\">",
"     32",
"    </a>",
"    ]. Resolution with antimicrobial therapy alone was observed in most patients with renal abscesses &lt;3 cm and 3 to 5 cm (100 and 92 percent, respectively). Those with abscesses &gt;5 cm did equally well with percutaneous or open surgical drainage.",
"   </p>",
"   <p>",
"    For abscesses that are not amenable to percutaneous drainage, surgical drainage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rescue nephrectomy may be required in severe cases for which medical treatment has failed. Consultation with urologic expertise should be pursued when an abscess occurs in the context of an anatomic abnormality (such as large, obstructing renal stones or vesicoureteral reflux) or when it is too large for effective treatment with antibiotics and catheter drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. Nephrectomy may also be warranted if the abscess develops in a small, chronically pyelonephritic and poorly functioning kidney destroyed by previous episodes of infection.",
"   </p>",
"   <p>",
"    Drainage catheters should remain in place until drainage is minimal (usually up to seven days). Follow-up imaging should be performed in the setting of persistent clinical symptoms and laboratory abnormalities or if drainage is not proceeding as expected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1588293396\">",
"    <span class=\"h3\">",
"     Perinephric abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with perinephric abscess should undergo percutaneous drainage (preferably CT or US-guided) for both diagnostic and therapeutic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14134/abstract/30,34,35\">",
"     30,34,35",
"    </a>",
"    ]. If prompt drainage is feasible, ideally it should be performed prior to initiation of antimicrobial therapy, so that Gram stain and culture results can be used to guide selection of therapy. If drainage cannot be performed promptly, empiric antibiotic therapy should be initiated as outlined in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of abscess presenting in association with pyelonephritis, empiric therapy should be targeted against Enterobacteriaceae, whereas if abscess presents in association with staphylococcal bacteremia, therapy should be targeted against this pathogen. Subsequently the initial antibiotic regimen should be tailored to culture and susceptibility results. Antibiotic options are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef74492 \" href=\"UTD.htm?9/62/10220\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Antibiotic therapy should be continued during and after drainage for a total duration of at least two to three weeks. The final duration of antibiotic therapy should be determined by the extent of infection, the patient's clinical response to initial management, and normalization of inflammatory markers (ESR and CRP).",
"   </p>",
"   <p>",
"    Patients with abscess(es) that are difficult to drain or slow to resolve on follow-up imaging may require longer courses of antibiotic therapy, tailored to resolution of clinical symptoms. Useful clinical parameters to follow include temperature, flank pain, white blood cell count, ESR and CRP.",
"   </p>",
"   <p>",
"    Following catheter removal, the antibiotic course for Enterobacteriaceae can be completed with oral therapy guided by culture results (",
"    <a class=\"graphic graphic_table graphicRef58686 \" href=\"UTD.htm?10/58/11179\">",
"     table 2",
"    </a>",
"    ). However, treatment of S. aureus metastatic infection should be completed with parenteral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal and perinephric abscess are complications of urinary tract infection that occur either in the setting of ascending infection with obstructed pyelonephritis (usually due to gram negative enteric bacilli) or in the setting of bacteremia with hematogenous seeding (usually due to Staphylococcus aureus). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of renal and perinephric abscess are similar to those of acute pyelonephritis: fever, flank pain, abdominal pain, dysuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      frequency. Renal or perinephric abscess may also present insidiously with few or no symptoms, particularly in the elderly and in individuals with autonomic neuropathy (usually in the setting of diabetes or chronic alcoholism). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood and urine cultures should be collected at presentation. Urinalysis usually demonstrates pyuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria in the setting of renal abscess that develops following progression of acute pyelonephritis, although urine studies may be normal if abscess develops as result of hematogenous spread or does not communicate with the collecting system. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiography should be used for definitive diagnosis of renal or perinephric abscess; the most useful modalities are computed tomography and ultrasonography. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with renal or perinephric abscess should be treated with antibiotics. For abscess presenting in association with pyelonephritis, empiric therapy should be targeted against Enterobacteriaceae; for abscess presenting in association with staphylococcal bacteremia, therapy should be targeted against staphylococci (",
"      <a class=\"graphic graphic_table graphicRef74492 \" href=\"UTD.htm?9/62/10220\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drainage is indicated if patients are septic or are not improving with antibiotic therapy and is more likely to be needed with larger perinephric or renal abscesses. Percutaneous drainage is generally preferred if possible because of decreased morbidity compared with surgical drainage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For renal abscesses &lt;5 cm in diameter, we suggest deferring drainage pending the outcome of initial antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If clinical symptoms and radiographic findings persist after several days of appropriate antimicrobial therapy, percutaneous drainage should be considered. In particularly severe cases, rescue nephrectomy may be required (particularly in diabetics). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial regimen should be tailored to culture and susceptibility results. Antibiotic therapy should be continued for at least 2 to 3 weeks, although duration is tailored to individual patient circumstances depending on timing of clinical and laboratory improvement and abscess resolution. Following removal of the drainage catheter, the antibiotic course for Enterobacteriaceae can be completed with oral therapy guided by culture results (",
"      <a class=\"graphic graphic_table graphicRef58686 \" href=\"UTD.htm?10/58/11179\">",
"       table 2",
"      </a>",
"      ). However, treatment of S. aureus metastatic infection should be completed with parenteral therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/1\">",
"      Coelho RF, Schneider-Monteiro ED, Mesquita JL, et al. Renal and perinephric abscesses: analysis of 65 consecutive cases. World J Surg 2007; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/2\">",
"      Shu T, Green JM, Orihuela E. Renal and perirenal abscesses in patients with otherwise anatomically normal urinary tracts. J Urol 2004; 172:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/3\">",
"      Dembry LM, Andriole VT. Renal and perirenal abscesses. Infect Dis Clin North Am 1997; 11:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/4\">",
"      Fowler JE Jr, Perkins T. Presentation, diagnosis and treatment of renal abscesses: 1972-1988. J Urol 1994; 151:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/5\">",
"      Hoverman IV, Gentry LO, Jones DW, Guerriero WG. Intrarenal abscess. Report of 14 cases. Arch Intern Med 1980; 140:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/6\">",
"      Hutchison FN, Kaysen GA. Perinephric abscess: the missed diagnosis. Med Clin North Am 1988; 72:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/7\">",
"      Sheinfeld J, Erturk E, Spataro RF, Cockett AT. Perinephric abscess: current concepts. J Urol 1987; 137:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/8\">",
"      Yen DH, Hu SC, Tsai J, et al. Renal abscess: early diagnosis and treatment. Am J Emerg Med 1999; 17:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/9\">",
"      Tsukagoshi D, Dinkovski B, Dasan S, Jethwa J. Perinephric abscess secondary to a staghorn calculus presenting as a subcutaneous abscess. CJEM 2006; 8:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/10\">",
"      Meyrier A, Guibert J. Diagnosis and drug treatment of acute pyelonephritis. Drugs 1992; 44:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/11\">",
"      Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician 2005; 71:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/12\">",
"      Fair WR, Higgins MH. Renal abscess. J Urol 1970; 104:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/13\">",
"      Siroky MB, Moylan R, Austen G Jr, Olsson CA. Metastatic infection secondary to genitourinary tract sepsis. Am J Med 1976; 61:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/14\">",
"      Lee BK, Crossley K, Gerding DN. The association between Staphylococcus aureus bacteremia and bacteriuria. Am J Med 1978; 65:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/15\">",
"      Browne RF, Zwirewich C, Torreggiani WC. Imaging of urinary tract infection in the adult. Eur Radiol 2004; 14 Suppl 3:E168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/16\">",
"      Demertzis J, Menias CO. State of the art: imaging of renal infections. Emerg Radiol 2007; 14:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/17\">",
"      Haddad MC, Hawary MM, Khoury NJ, et al. Radiology of perinephric fluid collections. Clin Radiol 2002; 57:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/18\">",
"      Reese JH, Anderson RU, Friedland G. Splenic abscess arising by direct extension from a perinephric abscess. Urol Radiol 1990; 12:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/19\">",
"      Saiki J, Vaziri ND, Barton C. Perinephric and intranephric abscesses: a review of the literature. West J Med 1982; 136:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/20\">",
"      Bova JG, Potter JL, Arevalos E, et al. Renal and perirenal infection: the role of computerized tomography. J Urol 1985; 133:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/21\">",
"      Kaplan DM, Rosenfield AT, Smith RC. Advances in the imaging of renal infection. Helical CT and modern coordinated imaging. Infect Dis Clin North Am 1997; 11:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/22\">",
"      Huang JJ, Sung JM, Chen KW, et al. Acute bacterial nephritis: a clinicoradiologic correlation based on computed tomography. Am J Med 1992; 93:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/23\">",
"      Kobayashi A, Utsunomiya Y, Kono M, et al. Malakoplakia of the kidney. Am J Kidney Dis 2008; 51:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/24\">",
"      Stanton MJ, Maxted W. Malacoplakia: a study of the literature and current concepts of pathogenesis, diagnosis and treatment. J Urol 1981; 125:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/25\">",
"      van Crevel R, Curfs J, van der Ven AJ, et al. Functional and morphological monocyte abnormalities in a patient with malakoplakia. Am J Med 1998; 105:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/26\">",
"      Rathore MH, Barton LL, Luisiri A. Acute lobar nephronia: a review. Pediatrics 1991; 87:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/27\">",
"      Rosenfield AT, Glickman MG, Taylor KJ, et al. Acute focal bacterial nephritis (acute lobar nephronia). Radiology 1979; 132:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/28\">",
"      Talner LB, Davidson AJ, Lebowitz RL, et al. Acute pyelonephritis: can we agree on terminology? Radiology 1994; 192:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/29\">",
"      Meng MV, Mario LA, McAninch JW. Current treatment and outcomes of perinephric abscesses. J Urol 2002; 168:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/30\">",
"      Lang EK. Renal, perirenal, and pararenal abscesses: percutaneous drainage. Radiology 1990; 174:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/31\">",
"      Deyoe LA, Cronan JJ, Lambiase RE, Dorfman GS. Percutaneous drainage of renal and perirenal abscesses: results in 30 patients. AJR Am J Roentgenol 1990; 155:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/32\">",
"      Siegel JF, Smith A, Moldwin R. Minimally invasive treatment of renal abscess. J Urol 1996; 155:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/33\">",
"      Dalla Palma L, Pozzi-Mucelli F, Ene V. Medical treatment of renal and perirenal abscesses: CT evaluation. Clin Radiol 1999; 54:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/34\">",
"      Gerzof SG, Gale ME. Computed tomography and ultrasonography for diagnosis and treatment of renal and retroperitoneal abscesses. Urol Clin North Am 1982; 9:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14134/abstract/35\">",
"      Kuligowska E, Newman B, White SJ, Caldarone A. Interventional ultrasound in detection and treatment of renal inflammatory disease. Radiology 1983; 147:521.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8057 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14134=[""].join("\n");
var outline_f13_51_14134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Renal abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1588293396\">",
"      - Perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8057|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/29/6609\" title=\"diagnostic image 1\">",
"      Renal abscess US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/14/36079\" title=\"diagnostic image 2\">",
"      Renal abscess CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/11/43184\" title=\"diagnostic image 3\">",
"      Perinephric abscess CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/48/1793\" title=\"diagnostic image 4\">",
"      Extending perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8057|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/62/10220\" title=\"table 1\">",
"      Parent rx renal abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/58/11179\" title=\"table 2\">",
"      Oral rx renal abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=related_link\">",
"      Emphysematous urinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16804?source=related_link\">",
"      Xanthogranulomatous pyelonephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_51_14135="Clinical manifestations and diagnosis of Rocky Mountain spotted fever";
var content_f13_51_14135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/51/14135/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14135/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/51/14135/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14135/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14135/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/51/14135/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14135/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/51/14135/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 16, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rocky Mountain spotted fever (RMSF) is a potentially lethal but usually curable tick-borne disease. It is the most common rickettsial infection in the United States. The etiologic agent, Rickettsia rickettsii, is a gram-negative, obligate intracellular bacterium with tropism for human endothelial cells. The clinical spectrum of human infection with R. rickettsii ranges from mild to fulminant. The epidemiology, clinical manifestations, and diagnosis of RMSF will be reviewed here. The basic biology of R. rickettsii infection, the mechanisms of disease, and the treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=see_link\">",
"     \"Biology of Rickettsia rickettsii infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14725?source=see_link\">",
"     \"Treatment of Rocky Mountain spotted fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Geography",
"    </span>",
"    &nbsp;&mdash;&nbsp;RMSF occurs throughout the United States, in Canada, Mexico, Central America, and in parts of South America (Bolivia, Argentina, Brazil, and Colombia). In the United States, RMSF is most prevalent in the southeastern and south central states. In 2007, there were 2221 cases of RMSF reported to the Centers for Disease Control and Prevention (CDC); this represented an increase from the 1130 cases reported in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/1\">",
"     1",
"    </a>",
"    ]. The estimated national average annual incidence of RMSF was 2.2 cases per million persons in 2003, but incidence varied by geographic area from 1 to",
"    <span class=\"nowrap\">",
"     &gt;15/100,000",
"    </span>",
"    persons (",
"    <a class=\"graphic graphic_figure graphicRef68225 \" href=\"UTD.htm?16/16/16647\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, epidemiologic studies that attempt to assess the frequency of RMSF have been hampered by the fact that serologic assays that do not distinguish RMSF from other spotted fever group rickettsiae species and by imprecise case definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An outbreak of RMSF in 16 patients from 2002 through 2004 was reported from rural eastern Arizona, a state that had previously only rarely reported the disease (three cases from 1981 through 2001) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/5\">",
"     5",
"    </a>",
"    ]. Of these patients, 13 (81 percent) were children &le;12 years of age; all had contact with tick-infested dogs (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Transmission'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Although RMSF is more common in rural and suburban locations, it also may occasionally occur in residents of urban areas. For example, cases of RMSF have been described in New York City in patients who presumably acquired the infection from tick bites in urban parks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/6\">",
"     6",
"    </a>",
"    ]. The ease and frequency of interstate travel means that patients with RMSF acquired in endemic areas may present to physicians practicing in locations where RMSF is uncommon or unknown. In addition, family clusters of infection are a well-recognized feature of RMSF because of shared residence and risks for vector exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An investigation of clusters of cases in Tennessee and North Carolina concluded that significant geographic differences in disease severity were present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/9\">",
"     9",
"    </a>",
"    ]. Similar clusters of severe disease have been reported in several locations in South America [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Seasonal variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of RMSF occur in the spring and early summer, when outdoor activity is most frequent. However, rare cases are seen in the cold weather months in residents of the southern United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/11\">",
"     11",
"    </a>",
"    ]. Whether these \"out of season\" cases are due to infection with R. rickettsii or other more benign spotted fever group rickettsiae has recently been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of reported cases of RMSF is highest among males. Although previous studies found that the highest incidence of RMSF occurred in children &lt;10 years, surveillance during 2003 demonstrated the highest age-specific incidence was among persons aged 40 and 64 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/12\">",
"     12",
"    </a>",
"    ]. Individuals with frequent exposure to dogs and who reside near wooded areas or areas with high grass are probably also at increased risk for infection.",
"   </p>",
"   <p>",
"    A retrospective study utilizing a national surveillance database found that the incidence of RMSF among American Indians was",
"    <span class=\"nowrap\">",
"     16.8/100,000",
"    </span>",
"    during the period from 2000 to 2005. In contrast, the incidence among whites and blacks was 4.2 and",
"    <span class=\"nowrap\">",
"     2.6/100,000,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Route",
"    </span>",
"    &nbsp;&mdash;&nbsp;RMSF is usually transmitted via a tick bite; tick bites are painless and many occur in body areas obscured by hair or skin folds. Thus it is not surprising that up to one-third of patients with proven RMSF do not recall a recent tick bite or recent tick contact [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Transmission rarely occurs from infective tick tissues or feces by conjunctival contamination, transcutaneous transmission, or inhalation (eg, after crushing blood-engorged ticks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vectors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal vector of RMSF in the eastern and south central United States is Dermacentor variabilis (the American dog tick) (",
"    <a class=\"graphic graphic_picture graphicRef71719 \" href=\"UTD.htm?19/57/20383\">",
"     picture 1",
"    </a>",
"    ). In contrast, Dermacentor andersoni (the Rocky Mountain wood tick) (",
"    <a class=\"graphic graphic_picture graphicRef68829 \" href=\"UTD.htm?21/18/21806\">",
"     picture 2",
"    </a>",
"    ) is the primary vector in the mountain states west of the Mississippi River.",
"   </p>",
"   <p>",
"    Rhipicephalus sanguineus, the common brown dog tick (",
"    <a class=\"graphic graphic_picture graphicRef72221 \" href=\"UTD.htm?2/23/2431\">",
"     picture 3",
"    </a>",
"    ), is also a vector for RMSF in some areas of the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/5\">",
"     5",
"    </a>",
"    ]. This tick was implicated in the outbreak of RMSF in rural eastern Arizona, noted above. R. sanguineus ticks in all life-stages of growth were abundantly found in and around many of the patients' homes and R. rickettsii was detected on polymerase chain reaction (PCR) and cultured from engorged and nonengorged ticks. Neither of the primary vectors for RMSF in the United States, D. variabilis nor D. andersonii ticks, was recovered from the homesites. Although the ecology of rural eastern Arizona that allowed the infestation of R. sanguineous ticks may not be generalizable to other regions of the United States, the R. sanguineus tick is widely distributed across North America, and should be considered as a potential vector. The Cayenne tick (Amblyomma cajennense) is a vector for R. rickettsii transmission in Central and South America. The yellow dog tick (Amblyomma aureolatum) has also been implicated as a vector in Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27349887\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infected patients become symptomatic 2 to 14 days after being bitten by an infected tick, with most cases occurring between five and seven days after exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Early nonspecific symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early phases of illness, most patients have nonspecific signs and symptoms such as fever (in virtually all cases), headache (often severe), malaise, myalgias, arthralgias, and nausea with or without vomiting (each in about 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/17\">",
"     17",
"    </a>",
"    ]. Some patients, especially children, may also have prominent abdominal pain that may be severe and may lead to erroneous diagnoses such as acute appendicitis, cholecystitis, and even bowel obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A small number of patients in the early phases of RMSF have been admitted to surgical services and some have undergone laparotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with RMSF develop a rash between the third and fifth days of illness (",
"    <a class=\"graphic graphic_picture graphicRef58061 \" href=\"UTD.htm?39/20/40270\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/8,17\">",
"     8,17",
"    </a>",
"    ]. However, only 14 percent of patients have rash on the first day, and less than one-half develop a rash in the first 72 hours of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/20\">",
"     20",
"    </a>",
"    ]. As a result, rash is often absent when patients first contact a physician [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In a small percentage of patients, the rash is delayed in onset past five days",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    is atypical (eg, confined to one body region).",
"   </p>",
"   <p>",
"    A potential diagnostic problem is that rash never occurs in up to 10 percent of patients. These cases of \"spotless\" RMSF may be severe and end fatally [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, the rash can be easily overlooked in dark-skinned individuals. These observations are important clinically because a delay in the institution of antimicrobial therapy beyond five days is associated with an increased mortality rate (22.9 versus 6.5 percent in those treated earlier in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14725?source=see_link\">",
"     \"Treatment of Rocky Mountain spotted fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical rash of RMSF begins on the ankles and wrists and spreads both centrally and to the palms and soles. The evolution of skin rash may vary among patients. Although the rash commonly begins as a maculopapular eruption and then becomes petechial, some patients may suddenly develop a petechial rash without a prior maculopapular eruption. Urticaria and pruritus are not characteristic of RMSF and their presence makes the diagnosis unlikely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to early nonspecific symptoms, abdominal pain, and rash, cough, bleeding, edema (especially in children), confusion, focal neurologic signs, and seizures may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/18\">",
"     18",
"    </a>",
"    ]. Conjunctivitis, retinal abnormalities, and electrocardiographic abnormalities may also rarely occur and lead to diagnostic confusion. The presence or absence of individual clinical manifestations is in part dependent upon the duration of illness. As an example, physicians in referral centers often see patients late in the course and are more likely to observe symptoms such as abnormal mentation, seizures, and focal neurologic deficits such as cranial nerve palsies or transient deafness. Gangrene of the digits, ears, and scrotum can also occur in severe cases, as can widespread organ dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated 612 deaths were attributable to RMSF in the United States between 1983 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/25\">",
"     25",
"    </a>",
"    ]. The case-fatality rate was highest in the very young (&le;4 years, 3 to 4 percent) and elderly persons (&ge;60 years, 4 to 9 percent) (",
"    <a class=\"graphic graphic_figure graphicRef52138 \" href=\"UTD.htm?27/45/28382\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the protean clinical features of RMSF, it is not surprising that this disorder is often confused with a wide array of other conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RMSF is commonly mistaken for an undifferentiated viral illness during the first few days of illness. If penicillin or a cephalosporin is administered empirically during this phase of illness, the subsequent rash may then be incorrectly diagnosed as a drug eruption.",
"     </li>",
"     <li>",
"      RMSF has been confused with measles, meningococcemia, infectious mononucleosis, viral hepatitis, leptospirosis, streptococcal infection, parvovirus infection (Fifth disease), roseola, enteroviral infection, and viral meningitis. In tropical areas typhoid fever, leptospirosis, and even dengue may be confused with RMSF.",
"     </li>",
"     <li>",
"      The clinical features of RMSF overlap with those of both monocytic ehrlichiosis and granulocytic anaplasmosis. Distinguishing between RMSF and ehrlichiosis on the basis of clinical features may be impossible, although the presence of leukopenia and the absence of rash are more typical of ehrlichiosis (",
"      <a class=\"graphic graphic_table graphicRef50677 \" href=\"UTD.htm?19/42/20141\">",
"       table 1",
"      </a>",
"      ). The preferred treatment of ehrlichiosis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      , is the same as that of RMSF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"       \"Human ehrlichiosis and anaplasmosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14725?source=see_link\">",
"       \"Treatment of Rocky Mountain spotted fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One study reported that a proposed new rickettsial species (Rickettsia amblyommii) present in the tick Ambylomma americanum may be in fact responsible for some illnesses in North Carolina that are identical in their clinical presentation to infection with R. rickettsii [",
"      <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/27\">",
"       27",
"      </a>",
"      ]. At present this report remains unconfirmed and of unknown significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RMSF is based upon the probability that individual clinical features represent RMSF in the appropriate epidemiologic setting, as with suggestive symptoms in an endemic area in the spring or early summer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/28\">",
"     28",
"    </a>",
"    ]. There is no completely reliable diagnostic test in the early phases of illness when therapy should be begun. Later, the diagnosis can be made by skin biopsy and confirmed serologically. Rickettsial blood cultures are highly sensitive and specific but are only available in research centers with specialized laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with RMSF have a normal white blood cell count at presentation. However, the white blood cell count may be low, normal, or elevated in individual patients and is therefore not diagnostically helpful. As the illness progresses, thrombocytopenia becomes more prevalent and may be severe; it is thought to result from increased destruction at sites of rickettsia-mediated vascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/20\">",
"     20",
"    </a>",
"    ]. The low platelet count may be accompanied by a reduced fibrinogen concentration and elevated fibrin split products; however, true disseminated intravascular coagulation is rare.",
"   </p>",
"   <p>",
"    Other findings that are common in advanced cases include hyponatremia, elevations in serum aminotransferases and bilirubin, azotemia, and prolongation of the partial thromboplastin and prothrombin times [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/18\">",
"     18",
"    </a>",
"    ]. In a small number of cases, jaundice and renal failure dominate and confuse the clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/24,29\">",
"     24,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 114 patients from our hospital, 19 percent developed acute renal failure (defined as an elevation in the serum creatinine concentration above 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [177",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/29\">",
"     29",
"    </a>",
"    ]. A variety of mechanisms may contribute to this complication, including hypotension-induced acute tubular necrosis, intravascular thrombosis, and interstitial vascular inflammation due to direct infection of the endothelial cells by R. rickettsii. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=see_link\">",
"     \"Biology of Rickettsia rickettsii infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a lumbar puncture is performed in a patient with RMSF, cerebrospinal fluid (CSF) analysis usually shows a white blood count (WBC) of &lt;100 cells per microL with either a polymorphonuclear or lymphocytic predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/18\">",
"     18",
"    </a>",
"    ]. Moderately elevated protein (100 to 200",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and a normal glucose level are common [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These findings may not help distinguish RMSF from meningococcal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of a skin lesion obtained with a 3 mm punch biopsy can establish the diagnosis of RMSF. Fresh or formaldehyde-fixed tissue should be examined for rickettsiae using direct immunofluorescence or immunoenzyme methods [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/32\">",
"     32",
"    </a>",
"    ]. Direct immunofluorescence staining can provide an answer in a few hours if the necessary conjugates are available locally. If local facilities are not able to do direct immunofluorescence, reference laboratories can perform immunoperoxidase stains on fixed tissue specimens. However, the delay in obtaining results makes this technique of little or no use for initial patient management.",
"   </p>",
"   <p>",
"    The sensitivity of detecting R. rickettsii in skin biopsies by direct immunofluorescence staining is approximately 70 percent with a specificity of 100 percent; however, the sensitivity rapidly declines after antirickettsial therapy is begun [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/32\">",
"     32",
"    </a>",
"    ]. It is therefore not useful to obtain a skin biopsy in patients who have received a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    for more than 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RMSF is best confirmed serologically using the indirect fluorescent antibody (IFA) test [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/33\">",
"     33",
"    </a>",
"    ]. IFA testing is available through all state health departments and through several large reference laboratories. Antibodies typically appear 7 to 10 days after the onset of the illness, and the optimal time to obtain a convalescent antibody titer is at 14 to 21 days after the onset of symptoms. The minimum diagnostic titer in most laboratories is 1:64.",
"   </p>",
"   <p>",
"    The overall sensitivity of the IFA test is approximately 95 percent. However, there are two settings in which false negative results are more likely:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serologic testing is usually not helpful during the first five days of symptoms, when therapy should be initiated, because the antibody response is not yet detectable [",
"      <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small percentage of patients who are treated within the first 48 hours after symptoms have begun may not develop convalescent antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the IFA is sensitive, serologic assays are insufficient to identify conclusively the specific rickettsial agent responsible for the infection. A study of 15 serum specimens with antibodies reactive with R. rickettsii from the CDC examined the specimens by microimmunofluorescence and Western blot assays against antigens of R. rickettsii and R. parkeri [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/34\">",
"     34",
"    </a>",
"    ]. Four patients had higher titers of antibody to R. rickettsii, five had higher titers to R. parkeri, and in six patients titers were equivalent to both rickettsial pathogens. Thus, spotted fever group rickettsiae, other than R. rickettsii, may be responsible for cases of tick-borne rickettsiosis in the United States.",
"   </p>",
"   <p>",
"    Other serologic tests that may be employed include enzyme immunoassay (EIA), complement fixation (CF) and latex agglutination (LA), indirect hemagglutination (IHA) or microagglutination (MA) assays. A probable diagnosis of RMSF may be established with a titer of 1:128 or greater by LA, IHA, or MA.",
"   </p>",
"   <p>",
"    The Weil-Felix test, which detects crossreacting antibodies against Proteus vulgaris antigens (OX2 and OX19), lacks sensitivity and specificity and its use is no longer recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14135/abstract/17,33\">",
"     17,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27350021\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rocky Mountain spotted fever (RMSF) is a potentially lethal but usually curable tick-borne disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RMSF occurs throughout the United States, Canada, Mexico, Central America, and in parts of South America (Bolivia, Argentina, Brazil, and Colombia). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Geography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of RMSF occur in the spring and early summer, when outdoor activity is most frequent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Seasonal variation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RMSF is usually transmitted via a tick bite, although up to one-third of patients with proven RMSF do not recall a recent tick bite or recent tick contact. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the early phases of illness, most patients have nonspecific signs and symptoms such as fever, headache, malaise, myalgias, arthralgias, and nausea with or without vomiting. Children may also have prominent abdominal pain that may be mistaken for other intraabdominal processes, like appendicitis. Most patients with RMSF develop a rash between the third and fifth days of illness. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of RMSF is a clinical one based on a constellation of symptoms that is consistent with the clinical presentation in an appropriate epidemiologic setting (eg, an endemic area in the spring or early summer). There is no completely reliable diagnostic test in the early phases of illness when therapy should be initiated. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In later illness, the diagnosis can be made by skin biopsy and confirmed serologically. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.cdc.gov/mmwr/PDF/wk/mm5653.pdf (Accessed December 2, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/2\">",
"      Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/3\">",
"      Raoult D, Parola P. Rocky Mountain spotted fever in the USA: a benign disease or a common diagnostic error? Lancet Infect Dis 2008; 8:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/4\">",
"      Graf PC, Chretien JP, Ung L, et al. Prevalence of seropositivity to spotted fever group rickettsiae and Anaplasma phagocytophilum in a large, demographically diverse US sample. Clin Infect Dis 2008; 46:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/5\">",
"      Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med 2005; 353:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/6\">",
"      Salgo MP, Telzak EE, Currie B, et al. A focus of Rocky Mountain spotted fever within New York City. N Engl J Med 1988; 318:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/7\">",
"      Jones TF, Craig AS, Paddock CD, et al. Family cluster of Rocky Mountain spotted fever. Clin Infect Dis 1999; 28:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Fatal cases of Rocky Mountain spotted fever in family clusters--three states, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/9\">",
"      Adjemian JZ, Krebs J, Mandel E, McQuiston J. Spatial clustering by disease severity among reported Rocky Mountain spotted fever cases in the United States, 2001-2005. Am J Trop Med Hyg 2009; 80:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/10\">",
"      Paddock CD, Fernandez S, Echenique GA, et al. Rocky Mountain spotted fever in Argentina. Am J Trop Med Hyg 2008; 78:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/11\">",
"      Lange JV, Walker DH, Wester TB. Documented Rocky Mountain spotted fever in Wintertime. JAMA 1982; 247:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/12\">",
"      Hopkins RS, Jajosky RA, Hall PA, et al. Summary of notifiable diseases--United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/13\">",
"      Holman RC, McQuiston JH, Haberling DL, Cheek JE. Increasing incidence of Rocky Mountain spotted fever among the American Indian population in the United States. Am J Trop Med Hyg 2009; 80:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/14\">",
"      Treadwell TA, Holman RC, Clarke MJ, et al. Rocky Mountain spotted fever in the United States, 1993-1996. Am J Trop Med Hyg 2000; 63:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/15\">",
"      Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995; 52:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/16\">",
"      Dantas-Torres F. Rocky Mountain spotted fever. Lancet Infect Dis 2007; 7:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/17\">",
"      Kirk JL, Fine DP, Sexton DJ, Muchmore HG. Rocky Mountain spotted fever. A clinical review based on 48 confirmed cases, 1943-1986. Medicine (Baltimore) 1990; 69:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/18\">",
"      Buckingham SC, Marshall GS, Schutze GE, et al. Clinical and laboratory features, hospital course, and outcome of Rocky Mountain spotted fever in children. J Pediatr 2007; 150:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/19\">",
"      Walker DH, Lesesne HR, Varma VA, Thacker WC. Rocky Mountain spotted fever mimicking acute cholecystitis. Arch Intern Med 1985; 145:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/20\">",
"      Helmick CG, Bernard KW, D'Angelo LJ. Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis 1984; 150:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/21\">",
"      Kirkland KB, Wilkinson WE, Sexton DJ. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis 1995; 20:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/22\">",
"      Sexton DJ, Corey GR. Rocky Mountain \"spotless\" and \"almost spotless\" fever: a wolf in sheep's clothing. Clin Infect Dis 1992; 15:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/23\">",
"      Kirkland KB, Marcom PK, Sexton DJ, et al. Rocky Mountain spotted fever complicated by gangrene: report of six cases and review. Clin Infect Dis 1993; 16:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/24\">",
"      Conlon PJ, Procop GW, Fowler V, et al. Predictors of prognosis and risk of acute renal failure in patients with Rocky Mountain spotted fever. Am J Med 1996; 101:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/25\">",
"      Paddock CD, Holman RC, Krebs JW, Childs JE. Assessing the magnitude of fatal Rocky Mountain spotted fever in the United States: comparison of two national data sources. Am J Trop Med Hyg 2002; 67:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Consequences of delayed diagnosis of Rocky Mountain spotted fever in children--West Virginia, Michigan, Tennessee, and Oklahoma, May-July 2000. MMWR Morb Mortal Wkly Rep 2000; 49:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/27\">",
"      Apperson CS, Engber B, Nicholson WL, et al. Tick-borne diseases in North Carolina: is \"Rickettsia amblyommii\" a possible cause of rickettsiosis reported as Rocky Mountain spotted fever? Vector Borne Zoonotic Dis 2008; 8:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/28\">",
"      Walker DH. Rocky Mountain spotted fever: a seasonal alert. Clin Infect Dis 1995; 20:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/29\">",
"      Green WR, Walker DH, Cain BG. Fatal viscerotropic Rocky Mountain spotted fever. Report of a case diagnosed by immunofluorescence. Am J Med 1978; 64:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/30\">",
"      Gorman RJ, Saxon S, Snead OC 3rd. Neurologic sequelae of Rocky Mountain spotted fever. Pediatrics 1981; 67:354.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplowitz LG, Fischer JJ, Sparling PF. Rocky Mountain spotted fever: a clinical dilemma. In: Current Clinical Topics in Infectious Diseases, Remington JB, Swartz MH (Eds), McGraw-Hill, New York 1981. Vol 2, p.81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/32\">",
"      Walker DH, Burday MS, Folds JD. Laboratory diagnosis of Rocky Mountain spotted fever. South Med J 1980; 73:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/33\">",
"      Kaplan JE, Schonberger LB. The sensitivity of various serologic tests in the diagnosis of Rocky Mountain spotted fever. Am J Trop Med Hyg 1986; 35:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14135/abstract/34\">",
"      Raoult D, Paddock CD. Rickettsia parkeri infection and other spotted fevers in the United States. N Engl J Med 2005; 353:626.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7904 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14135=[""].join("\n");
var outline_f13_51_14135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27350021\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Geography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Seasonal variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vectors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27349887\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Early nonspecific symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27350021\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7904\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7904|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/16/16647\" title=\"figure 1\">",
"      Annual incidence RMSF map",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/45/28382\" title=\"figure 2\">",
"      Clinical manifestations RMSF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7904|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/57/20383\" title=\"picture 1\">",
"      American dog tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/18/21806\" title=\"picture 2\">",
"      Rocky mountain wood tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/23/2431\" title=\"picture 3\">",
"      Brown dog tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/20/40270\" title=\"picture 4\">",
"      RMSF rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7904|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/42/20141\" title=\"table 1\">",
"      Features of tickborne infx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=related_link\">",
"      Biology of Rickettsia rickettsii infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14725?source=related_link\">",
"      Treatment of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_51_14136="Transportation young CSHCN";
var content_f13_51_14136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    General guidelines for safe transportation of infants and young children with special health care needs*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FMVSS: Federal Motor Vehicle Safety Standards; NHTSA; National Highway Traffic Safety Administration.",
"     <br>",
"      * Consultation with a child passenger safety technician may be helpful; additional information and a national list of child passenger safety technicians can be found at www.preventinjury.org/specNeeds.asp.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bull, M, Agran, P, Laraque, D, et al. American Academy of Pediatrics. Committee on Injury and Poison Prevention. Transporting children with special health care needs. Pediatrics 1999; 104:988. (Reaffirmed May, 2006).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14136=[""].join("\n");
var outline_f13_51_14136=null;
var title_f13_51_14137="Myopathies of systemic disease";
var content_f13_51_14137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Myopathies of systemic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/51/14137/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14137/contributors\">",
"     David Lacomis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/51/14137/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14137/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/51/14137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/51/14137/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/51/14137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal muscle is a complex tissue that is composed of many structural proteins and several energy-producing pathways. Thus, it can be perturbed by a number of systemic disorders.",
"   </p>",
"   <p>",
"    This topic will review the myopathies associated with endocrine disease, malabsorption, electrolyte disturbance, critical illness, and rheumatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENDOCRINE MYOPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrine diseases are generally associated with hormonally-mediated systemic alterations in metabolism. At any time during the course of many endocrinopathies, muscle may become affected. The diagnosis of such a myopathy may be more difficult if it is the presenting manifestation of the endocrinopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hypothyroid myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle disease is a common complication of congenital and adult-onset hypothyroidism. Hypothyroid myopathy is briefly reviewed here and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link\">",
"     \"Hypothyroid myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hypothyroidism frequently complain of weakness with or without cramps and myalgias. Patients of all ages and either sex may be affected, but hypothyroidism and therefore hypothyroid myopathy is more common in women. Weakness may be an initial symptom of hypothyroidism, or it may occur years into the course of the endocrinopathy.",
"   </p>",
"   <p>",
"    Myopathic weakness in congenital hypothyroidism occurs in association with other manifestations of cretinism, is accompanied by prominent muscle hypertrophy, and responds to thyroid replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link&amp;anchor=H2#H2\">",
"     \"Hypothyroid myopathy\", section on 'Congenital hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, the severity of muscle disease can range from asymptomatic elevation of serum creatine kinase to disabling muscle weakness. In addition to proximal muscle weakness, neurologic findings include sluggish or hung-up reflexes, myoedema (expansion of muscle following direct percussion), and rarely, an increase in muscle bulk. In chronic hypothyroid myopathy, the triad of muscle hypertrophy, weakness, and creatine kinase elevation may occur. Rhabdomyolysis has been reported but occurs rarely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link&amp;anchor=H4#H4\">",
"     \"Hypothyroid myopathy\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of typical myopathic symptoms in the setting of hypothyroidism is sufficient to make the diagnosis. Electromyography is normal or shows myopathic changes. Muscle biopsy, if performed to exclude other conditions, shows nonspecific changes and only mild, if any, inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link&amp;anchor=H11#H11\">",
"     \"Hypothyroid myopathy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroid replacement usually leads to resolution of laboratory abnormalities and symptoms over a few to several weeks. Weakness may recover more slowly, over several months, and, in severely affected patients, may persist even longer. Pathologic changes in muscle may also persist after clinical recovery occurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link&amp;anchor=H13#H13\">",
"     \"Hypothyroid myopathy\", section on 'Treatment and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hyperthyroid myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness with or without atrophy and myalgias occurs in 60 to 80 percent of patients with untreated hyperthyroidism. This discussion will briefly review hyperthyroid myopathy. A more detailed discussion is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link&amp;anchor=H18#H18\">",
"     \"Neurologic manifestations of hyperthyroidism and Graves' disease\", section on 'Myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cramps are less common than with hypothyroidism. Patients with hyperthyroidism tend to develop muscle involvement more frequently after the age of 40. The likelihood of developing weakness, but not its degree, is correlated with the duration of the hyperthyroid state.",
"   </p>",
"   <p>",
"    About two-thirds of patients with hyperthyroid myopathy report proximal weakness that usually begins several weeks to several months after the onset of hyperthyroidism. Hip flexors and quadriceps may be predominantly affected. The remainder has distal as well as proximal muscle involvement. Bulbar and respiratory muscle dysfunction occurs rarely. Weakness is sometimes the sole manifestation of the endocrinopathy. Myalgias may occur. Deep tendon reflexes are normal or increased, an unusual finding in a myopathic disorder. Paresthesias, due to coexisting polyneuropathy, may be present.",
"   </p>",
"   <p>",
"    Laboratory testing usually shows a normal serum creatine kinase level; electromyography sometimes reveals \"myopathic\" motor unit potentials, but fibrillation potential activity is usually absent. Pathologic changes are typically nonspecific.",
"   </p>",
"   <p>",
"    Treatment involves returning the patient to euthyroidism. Patients generally improve fully within four months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cushing syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness is a common accompaniment of all types of hypercortisolism, both endogenous (Cushing syndrome and Cushing disease) and exogenous. The clinical features are similar in all of the cortisol excess states. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Muscle weakness in Cushing syndrome may be due to glucocorticoid-induced inhibition of protein synthesis with impairment in ribosome function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/1\">",
"     1",
"    </a>",
"    ]. Accelerated protein catabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/2\">",
"     2",
"    </a>",
"    ], changes in amino acid export from muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/3\">",
"     3",
"    </a>",
"    ], and alteration of carbohydrate metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/4\">",
"     4",
"    </a>",
"    ] are all likely to play a role. Altered gene regulation and cell signaling by steroid hormones probably leads to some of these metabolic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/5\">",
"     5",
"    </a>",
"    ]. There is also enhanced protein turnover mediated by the ubiquitin-proteosome proteolytic pathway, which is stimulated by glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, weakness with atrophy occurs insidiously in 50 to 90 percent of patients with Cushing syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Patients usually have other physical features of hypercortisolism such as \"moon facies.\" The weakness, which may or may not be accompanied by myalgias, is proximal in distribution, first affecting the lower extremities and then the upper extremities. Facial and bulbar muscles are generally not involved, and diaphragm weakness occurs rarely. This respiratory involvement can be severe, however [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On laboratory evaluation, the serum creatine kinase is normal. Electromyography is sometimes normal, but some short-duration, low-amplitude motor unit potentials, compatible with myopathy, are often detected. Occasionally, insertional activity is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major histologic finding is atrophy of type 2 muscle fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/12\">",
"     12",
"    </a>",
"    ], especially type 2B (high glycolytic, low oxidative potential) muscle fibers.",
"   </p>",
"   <p>",
"    Patients generally improve over months with treatment of the endocrinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. The greatest improvement occurs within three months, but strength and muscle mass may continue to increase for over a year. Improvement may be incomplete [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of Cushing syndrome depends on the etiology; options include pituitary or adrenal tumor removal, medical therapy to reduce hypothalamic corticotropin-releasing hormone, and chemical adrenalectomy. Physical therapy may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link\">",
"     \"Overview of the treatment of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe, subjective, generalized weakness has been described in up to 100 percent of patients with Addison's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Cramping and fatigue may also occur. Some patients develop lower extremity flexion contractures and myalgias as their primary complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Symptoms improve with the administration of glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adequate clinicopathologic studies are lacking; therefore, it is difficult to clearly categorize the weakness as myopathic.",
"   </p>",
"   <p>",
"    The mechanism of adrenal insufficiency-associated weakness is not established, but potential causes include changes in carbohydrate metabolism and electrolyte abnormalities (hyponatremia and hyperkalemia), a loss of exercise-induced glycogenolysis, and circulatory insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hyperaldosteronism with myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness is a very common complaint in patients with hyperaldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/19\">",
"     19",
"    </a>",
"    ], and it has been ascribed to potassium deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/20\">",
"     20",
"    </a>",
"    ]. On the other hand, objective weakness is rare, and in one report was seen in only one of 12 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/20\">",
"     20",
"    </a>",
"    ]. In another report describing two patients with hyperaldosteronism and myopathy, serum creatine kinase levels were elevated in both, and the electromyography findings were \"myopathic\" in one [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/21\">",
"     21",
"    </a>",
"    ]. Electron microscopy revealed dilatation of the T-tubule system and sarcoplasmic reticulum. Muscle strength improved with treatment of the underlying condition.",
"   </p>",
"   <p>",
"    Activity-dependent conduction block was identified in a patient with acute weakness and hyperaldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/22\">",
"     22",
"    </a>",
"    ]. This conduction block may contribute to weakness and paralysis in patients with hypokalemia and hyperaldosteronism.",
"   </p>",
"   <p>",
"    The general clinical features and treatment of primary aldosteronism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hyperparathyroid myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insidious development of proximal weakness (legs involved more than arms), fatigue, musculoskeletal pain, and hyperreflexia has been reported in approximately 25 percent of patients with primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with secondary hyperparathyroidism may be similarly affected, but a coexistent neuropathy is usually present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/4\">",
"     4",
"    </a>",
"    ]. Some patients with secondary hyperparathyroidism also have osteomalacia, which alone is commonly associated with myopathy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Osteomalacic myopathy and celiac sprue'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rarely, a malignant necrotizing myopathy with vascular calcifications occurs in patients with hyperparathyroidism and uremia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On laboratory testing, serum calcium, alkaline phosphatase, and parathyroid hormone (PTH) are elevated, while the serum creatine kinase is normal. Electromyography findings are mixed and include short-duration, low-amplitude motor unit potentials as well as high-amplitude, long-duration motor unit potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Limited reports of nerve conduction studies have been normal. Histopathologic studies of muscle reveal mostly atrophy of type 2 more than type 1 fibers.",
"   </p>",
"   <p>",
"    The pathogenesis of hyperparathyroid myopathy is uncertain. There may be a neuronal or motor axonal component. Increased regulators of calcium homeostasis, namely parathyroid hormone and vitamin D, may be important in inducing weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients usually regain strength within weeks of treatment of the endocrinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diabetic muscle infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic muscle infarction is a rare disorder that affects patients who have relatively longstanding diabetes, many of whom have other micro or macrovascular complications. Clinical manifestations include acute or subacute onset of muscle pain, swelling, and associated tenderness. The muscles of the thigh and calf are most commonly affected. Frequent but nonspecific laboratory findings include elevation of plasma CK enzyme activity, leukocytosis, and elevated ESR.",
"   </p>",
"   <p>",
"    Diabetic muscle infarction is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1526?source=see_link\">",
"     \"Diabetic muscle infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MYOPATHIES ASSOCIATED WITH MALABSORPTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Osteomalacic myopathy and celiac sprue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myopathy is common in osteomalacia, and proximal-predominant weakness is the initial symptom in about 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients often have pain, which may be partly of myopathic and partly of bone origin.",
"   </p>",
"   <p>",
"    Celiac sprue can present with osteomalacic myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Although neuropathy with or without ataxia are more common accompaniments of sprue, myopathy can be the primary neuromuscular presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/33\">",
"     33",
"    </a>",
"    ]. Histopathologic features may include muscle inflammation, suggesting an autoimmune component.",
"   </p>",
"   <p>",
"    Patients who develop malabsorption after gastric bypass can also develop vitamin D deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link\">",
"     \"Medical management of patients after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients typically have malabsorption with hypovitaminosis D, secondary hyperparathyroidism, and, eventually, bony abnormalities (pseudofractures). An elevation in serum alkaline phosphatase is a clue to diagnosis. The 25-dihydroxyvitamin D3 level is low, but 1,25-dihydroxyvitamin D3 may be normal if there is increased renal conversion of vitamin D to the dihydroxy form in the setting of hypophosphatemia and elevated parathyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The serum creatine kinase level is usually normal. Electromyography findings may be normal or may show some mild \"myopathic\" motor unit potential changes without fibrillation potentials.",
"   </p>",
"   <p>",
"    Histopathologic findings are nonspecific but may include type 2 muscle fiber atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to identify the underlying cause of osteomalacia so that the disorder can be corrected. Vitamin D and calcium supplementation are typically beneficial over a period of months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vitamin E deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E is fat-soluble and can be depleted in malabsorption states. Patients with celiac sprue and patients who have undergone gastric bypass surgery may be especially at risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of vitamin E\", section on 'Deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link\">",
"     \"Medical management of patients after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic complications of vitamin E deficiency include ataxia and peripheral neuropathy, but also myoclonus, dementia, epilepsy, and myopathy. In particular, a vacuolar myopathy with inflammation can be a consequence, although it is uncommon. Serum creatine kinase may be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin E supplementation and a gluten-free diet benefits celiac sprue patients who have vitamin E deficiency with neuropathy and myopathy. The myopathic component improves over a few months, and histologic improvement on muscle biopsy has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HYPOKALEMIC MYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vacuolar myopathy occurs in patients with repeated bouts of hypokalemic periodic paralysis.",
"   </p>",
"   <p>",
"    Paralysis from severe hypokalemia can also occur in some clinical settings, including chronic diarrhea, renal tubular acidosis, primary aldosteronism, and alcoholism. Certain drug and substance intoxications, from licorice, cola, and clay for example, can also trigger this phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weakness associated with hypokalemia can develop over hours to days, and usually affects proximal muscles. It may be associated with cramping. Rarely, the diaphragm, cranial, or posterior cervical muscles are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/43\">",
"     43",
"    </a>",
"    ]. Tendon reflexes may be diminished, and cardiac arrhythmias can also occur.",
"   </p>",
"   <p>",
"    Muscle membrane may become unexcitable and, eventually, myofiber vacuolation and necrosis can occur. The creatine kinase may be normal or slightly elevated. Electromyography may show \"myopathic\" motor unit potentials, which may be accompanied by fibrillation potentials.",
"   </p>",
"   <p>",
"    Administration of potassium is the appropriate treatment. Depending on the acuity and severity, intravenous verses oral replacement should be considered. Improvement begins over an hour or two, but patients with severe weakness may take weeks to improve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MYOPATHY ASSOCIATED WITH CRITICAL ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a critically ill patient who develops flaccid generalized weakness, the major considerations in the differential diagnosis are critical illness myopathy (CIM) and critical illness polyneuropathy (CIP), or a combination of the two termed polyneuromyopathy. Other considerations in the differential diagnosis include rhabdomyolysis, cachectic myopathy, and Guillain-Barr&eacute; syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=see_link\">",
"     \"Neuromuscular weakness related to critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Critical illness myopathy is the most common form of intensive care unit (ICU)-acquired myopathy. The main risk factor for CIM is the use of intravenous (IV) glucocorticoids in the ICU setting. However, there is increasing evidence that some critical patients develop CIM in the absence of exposure to IV glucocorticoids. CIM usually begins several days or so after ICU admission, especially after IV glucocorticoid treatment is initiated.",
"   </p>",
"   <p>",
"    Major electrophysiologic findings of CIM include normal to low-amplitude motor responses of prolonged duration and short-duration motor unit potentials coupled with normal or near-normal sensory potentials. Needle electromyography shows early or normal full recruitment. Some muscles exhibit electrical inexcitability to direct muscle stimulation. The major histopathologic findings are myopathy and myosin loss. Serum CK elevation is seen in approximately one-half of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=see_link&amp;anchor=H9#H9\">",
"     \"Neuromuscular weakness related to critical illness\", section on 'Laboratory and electrodiagnostic findings in CIM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CIM is usually reversible over weeks to months, but it leads to prolonged ICU stays and increased length of hospital stay overall. Treatment is directed toward discontinuation or reduction of glucocorticoids as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=see_link&amp;anchor=H13#H13\">",
"     \"Neuromuscular weakness related to critical illness\", section on 'Treatment and prognosis of CIM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MYOPATHIES IN RHEUMATIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The idiopathic inflammatory myopathies dermatomyositis and polymyositis may occur in the setting of systemic connective tissue diseases. These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inclusion body myositis occasionally occurs in patients with Sj&ouml;gren's syndrome. This disorder is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28133?source=see_link\">",
"     \"Treatment and prognosis of inclusion body myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, skeletal muscle can be affected by polymyalgia rheumatica, vasculitis, or amyloidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Polymyalgia rheumatica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with polymyalgia rheumatica (PMR) typically are over 50 years of age and have bilateral aching and stiffness in proximal muscles, hips, neck, or torso. The stiffness is usually noted in the morning. It is often difficult to determine whether there is proximal muscle weakness because the examination is limited by pain. The pain usually worsens with activity. Imaging studies suggest inflammation in synovial tissues. Systemic features are common, including anorexia, weight loss, and fatigue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .) The RS3PE (Remitting, Symmetric, Seronegative [for rheumatoid arthritis] Synovitis with Pitting Edema) syndrome may be considered a variant of PMR when it responds to low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . It may also be associated with neoplastic disorders or other rheumatic diseases. These patients may also present with \"weakness\" due to pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, some patients with PMR develop giant cell arteritis of the head and neck, potentially leading to headache, jaw claudication, anterior ischemic optic neuropathy, aortic aneurysm, cranial neuropathy, and even brachial plexopathy and stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typically, elevations in Westergren erythrocyte sedimentation rate (&gt;40",
"    <span class=\"nowrap\">",
"     mm/h)",
"    </span>",
"    and C-reactive protein are present. The serum creatine kinase level is normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electromyography is also normal. Muscle histopathology is either normal or reveals atrophy of type 2 muscle fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Microvascularization of muscle has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is usually a dramatic improvement with low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40598?source=see_link\">",
"     \"Treatment of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Skeletal muscle vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal muscle vasculitis typically occurs in association with either systemic vasculitis or isolated peripheral nervous system vasculitis. In either group, an associated vasculitic neuropathy is often the major peripheral nervous system clinical manifestation.",
"   </p>",
"   <p>",
"    About 55 percent or more of patients with vasculitis affecting skeletal muscle have substantial myalgias and some degree of weakness. They may also exhibit weight loss and fever, and some (about 20 percent in one series) will have paresthesias due to an associated peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients with systemic vasculitides may also have fever, arthralgias, and involvement of other organ systems.",
"   </p>",
"   <p>",
"    In polyarteritis nodosa, vascular occlusions and aneurysmal dilatations can affect digits and intra-abdominal organs. Other systemic vasculitides that may involve skeletal muscle include Churg-Strauss syndrome, Wegener's granulomatosis, hypersensitivity vasculitis, and microscopic polyarteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, patients with systemic lupus erythematosus, rheumatoid arthritis, scleroderma, HIV infection, and Sj&ouml;gren's syndrome can develop skeletal muscle vasculitis, often in conjunction with a vasculitic peripheral neuropathy. MRI may reveal increased signal on slow tau inversion recovery (STIR) sequences in affected muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"     \"Clinical manifestations of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Giant cell arteritis is only rarely associated with skeletal muscle vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with skeletal muscle vasculitis, the Westergren erythrocyte sedimentation rate is often, but not always, elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/47\">",
"     47",
"    </a>",
"    ]. Anemia and leukocytosis may be present. Other laboratory findings may reflect the presence of an underlying systemic disorder, such as anti-DNA antibodies in systemic lupus erythematosus, and anti-neutrophilic cytoplasmic bodies in patients with Wegener's granulomatosis and Churg-Strauss syndrome. Patients with polyarteritis nodosa may have associated hepatitis C or B virus infections.",
"   </p>",
"   <p>",
"    Histopathologically, vasculitis is identified by the presence of fibrinoid necrosis of the vessel wall in conjunction with transmural inflammation. There may be vascular occlusion in a minority [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/47\">",
"     47",
"    </a>",
"    ]. In all types of systemic vasculitis, macrophages and lymphocytes of various types are commonly noted.",
"   </p>",
"   <p>",
"    In polyarteritis nodosa, neutrophils may be seen within the inflammatory infiltrate, and, with Churg-Strauss syndrome, eosinophils are common. Giant cells are typically seen in the region of the internal elastic membrane in giant cell arteritis, and they are sometimes seen in other systemic vasculitides. With hypersensitivity vasculitis and vasculitis affecting small blood vessels, fibrinoid necrosis may not be evident, but there should be a transmural inflammatory infiltrate with nuclear debris.",
"   </p>",
"   <p>",
"    The vast majority of muscle specimens also reveal evidence of neurogenic atrophy. Regenerating and degenerating muscle fibers are also seen in approximately 40 percent of biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment depends upon the cause of vasculitis. The treatments are addressed in the individual sections regarding these disorders. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    In isolated peripheral nervous system vasculitis, treatment with corticosteroids alone is a consideration, but often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    will be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=see_link\">",
"     \"Diagnosis and treatment of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective series that excluded vasculitis associated with inflammatory myopathic conditions, such as polymyositis or dermatomyositis, 33 patients with skeletal muscle vasculitis underwent corticosteroid therapy, and 19 received additional immunosuppressants [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/47\">",
"     47",
"    </a>",
"    ]. At least 17 (52 percent) improved with combined corticosteroid and immunosuppressive therapy. Some were lost to follow-up and five died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Amyloid myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid myopathy is rare, but it may be underdiagnosed unless muscle biopsy specimens are routinely evaluated by the fluorescent Congo red stain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with amyloid myopathy usually have proximal weakness and an elevated serum creatine kinase level. Less than half of patients have enlarged muscles with or without macroglossia. Relatively uncommon features include distal weakness, muscle atrophy, focal axial myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/54\">",
"     54",
"    </a>",
"    ], respiratory dysfunction, claudication, and dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic features may include bruising, diarrhea, autonomic neuropathy, renal and cardiac dysfunction, and arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/52,56\">",
"     52,56",
"    </a>",
"    ]. MRI may identify distinctive reticulation of the subcutaneous fat [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean age at diagnosis is 60 years, but there is a wide range. The mean time to diagnosis is 22 months, reflecting the difficulty in recognition [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/55\">",
"     55",
"    </a>",
"    ]. The clinical, laboratory, and electrodiagnostic features may mimic an inflammatory myopathy.",
"   </p>",
"   <p>",
"    Nerve conduction studies may reveal low peroneal or tibial motor amplitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/58\">",
"     58",
"    </a>",
"    ]. Needle examination features include short duration motor unit potentials in all cases, and long duration motor unit potentials mainly in distal muscles in a minority [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/52,58\">",
"     52,58",
"    </a>",
"    ]. At least half exhibit fibrillation potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/52,58\">",
"     52,58",
"    </a>",
"    ]. Complex repetitive or myotonic discharges are uncommonly encountered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/58\">",
"     58",
"    </a>",
"    ]. There may be evidence of a coexisting axonal sensorimotor polyneuropathy or mononeuropathy such as carpal tunnel syndrome.",
"   </p>",
"   <p>",
"    Pathologically, there is amyloid deposition around small blood vessels, encasement of muscle fibers by amyloid, and mild muscle fiber necrosis and regeneration. Mild signs of denervation atrophy may be present, and inflammatory infiltrates are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/52,55\">",
"     52,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority with amyloid myopathy has light-chain immunoglobulin amyloidosis with or without multiple myeloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis of the underlying disorder is made by serum and urine protein immunoelectrophoresis and bone marrow analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H20#H20\">",
"     \"An overview of amyloidosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with amyloid myopathy have familial amyloidosis with mutations in gelsolin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/52\">",
"     52",
"    </a>",
"    ] and transthyretin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/59\">",
"     59",
"    </a>",
"    ]. Transthyretin gene mutations are typically associated with distal weakness and polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/59\">",
"     59",
"    </a>",
"    ], and age of onset may be earlier in familial forms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link\">",
"     \"Genetic factors in the amyloid diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis is poor. A minority of patients treated with alkylating agents, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , respond [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/56\">",
"     56",
"    </a>",
"    ], and mean survival is 22 months. [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/55\">",
"     55",
"    </a>",
"    ]. The role of more aggressive immunotherapies and stem cell transplant in treating amyloid myopathy is currently undetermined [",
"    <a class=\"abstract\" href=\"UTD.htm?13/51/14137/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H25#H25\">",
"     \"An overview of amyloidosis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535106583\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocrine diseases are generally associated with hormonally-mediated systemic alterations in metabolism. Muscle may become affected at any time during the course of several endocrinopathies. The diagnosis of such a myopathy may be more difficult if it is the presenting manifestation of the endocrinopathy. The range of endocrine disorders associated with myopathy includes the following conditions (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Endocrine myopathies'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypothyroidism (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Hypothyroid myopathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hyperthyroidism (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Hyperthyroid myopathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cushing Syndrome (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Cushing syndrome'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Adrenal Insufficiency (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Adrenal insufficiency'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hyperaldosteronism (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Hyperaldosteronism with myopathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hyperparathyroidism (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Hyperparathyroid myopathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Diabetes (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Diabetic muscle infarction'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myopathy is common in osteomalacia. Celiac sprue can present with osteomalacic myopathy. It is important to identify the underlying cause of osteomalacia so that the disorder can be corrected. Vitamin E is fat-soluble and can be depleted in malabsorption states; a vacuolar myopathy with inflammation can be a consequence, although it is uncommon. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Myopathies associated with malabsorption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A vacuolar myopathy occurs in patients with repeated bouts of hypokalemic periodic paralysis. Paralysis from severe hypokalemia can also occur in some clinical settings, including chronic diarrhea, renal tubular acidosis, primary aldosteronism, alcoholism, and certain drug and substance intoxications. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hypokalemic myopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a critically ill patient who develops flaccid generalized weakness, the major considerations in the differential diagnosis are critical illness myopathy and critical illness polyneuropathy, or a combination of the two termed polyneuromyopathy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Myopathy associated with critical illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The idiopathic inflammatory myopathies dermatomyositis and polymyositis may occur in the setting of systemic connective tissue diseases. Occasionally, skeletal muscle can be affected by polymyalgia rheumatica, vasculitis, or amyloidosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Myopathies in rheumatic diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/1\">",
"      Kelly FJ, McGrath JA, Goldspink DF, Cullen MJ. A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle. Muscle Nerve 1986; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/2\">",
"      Smith OL, Wong CY, Gelfand RA. Influence of glucocorticoids on skeletal muscle proteolysis in normal and diabetic-adrenalectomized eviscerated rats. Metabolism 1990; 39:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/3\">",
"      Almon RR, Dubois DC. Fiber-type discrimination in disuse and glucocorticoid-induced atrophy. Med Sci Sports Exerc 1990; 22:304.",
"     </a>",
"    </li>",
"    <li>",
"     Ruff RL. Endocrine myopathies. In: Myology, Engel AG, Banker BQ.  (Eds), McGraw Hill, New York 1986. p.1871.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/5\">",
"      Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000; 6:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/6\">",
"      Mitch WE, Bailey JL, Wang X, et al. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 1999; 276:C1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/7\">",
"      PLOTZ CM, KNOWLTON AI, RAGAN C. The natural history of Cushing's syndrome. Am J Med 1952; 13:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/8\">",
"      Urbanic RC, George JM. Cushing's disease--18 years' experience. Medicine (Baltimore) 1981; 60:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/9\">",
"      Blanco C, Marazuela M, Flores J, Alvarez J. Severe respiratory failure secondary to Cushing's myopathy. J Endocrinol Invest 2001; 24:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/10\">",
"      Olafsson E, Jones HR Jr, Guay AT, Thomas CB. Myopathy of endogenous Cushing's syndrome: a review of the clinical and electromyographic features in 8 patients. Muscle Nerve 1994; 17:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/11\">",
"      Lacomis D, Chad DA, Aronin N, Smith TW. The myopathy of Cushing's syndrome. Muscle Nerve 1993; 16:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/12\">",
"      Pleasure DE, Walsh GO, Engel WK. Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch Neurol 1970; 22:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/13\">",
"      Khaleeli AA, Betteridge DJ, Edwards RH, et al. Effect of treatment of Cushing's syndrome on skeletal muscle structure and function. Clin Endocrinol (Oxf) 1983; 19:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/14\">",
"      Falduto MT, Czerwinski SM, Hickson RC. Glucocorticoid-induced muscle atrophy prevention by exercise in fast-twitch fibers. J Appl Physiol 1990; 69:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/15\">",
"      Thorn, GW, Dorrance, SS, Day, E. Addison's Disease: Evaluation of synthetic desoxycorticosterone acetate therapy in 158 patients. Ann Intern Med 1942; 16:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/16\">",
"      Nerup J. Addison's disease--clinical studies. A report fo 108 cases. Acta Endocrinol (Copenh) 1974; 76:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/17\">",
"      Shapiro MS, Trebich C, Shilo L, Shenkman L. Myalgias and muscle contractures as the presenting signs of Addison's disease. Postgrad Med J 1988; 64:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/18\">",
"      Harbuz V, Bihan H, Salama J, et al. Flexion contractures possibly reflect the existence of hypocortisolism: two case reports. J Neurol 2010; 257:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/19\">",
"      CONN JW, KNOPF RF, NESBIT RM. CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES. Am J Surg 1964; 107:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/20\">",
"      RELMAN AS. DIAGNOSIS OF PRIMARY ALDOSTERONISM. Am J Surg 1964; 107:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/21\">",
"      Atsumi T, Ishikawa S, Miyatake T, Yoshida M. Myopathy and primary aldosteronism: electronmicroscopic study. Neurology 1979; 29:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/22\">",
"      Krishnan AV, Colebatch JG, Kiernan MC. Hypokalemic weakness in hyperaldosteronism: activity-dependent conduction block. Neurology 2005; 65:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/23\">",
"      Clinical conference: Hyperparathyroidism: recent studies. Ann Intern Med 1973; 79:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/24\">",
"      Gutman, AB, Swenson, PC, Parsons, WB. The differential diagnosis of hyperparathyroidism. JAMA 1934; 103:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/25\">",
"      De Luca GC, Eggers SD. A rare complication of azotemic hyperparathyroidism: ischemic calcific myopathy. Neurology 2010; 75:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/26\">",
"      Cholod EJ, Haust MD, Hudson AJ, Lewis FN. Myopathy in primary familial hyperparathyroidism. Clinical and morphologic studies. Am J Med 1970; 48:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/27\">",
"      BISCHOFF A, ESSLEN E. MYOPATHY WITH PRIMARY HYPERPARATHYROIDISM. Neurology 1965; 15:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/28\">",
"      Frame B, Heinze EG Jr, Block MA, Manson GA. Myopathy in primary hyperparathyroidism. Observations in three patients. Ann Intern Med 1968; 68:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/29\">",
"      Patten BM, Pages M. Severe neurological disease associated with hyperparathyroidism. Ann Neurol 1984; 15:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/30\">",
"      Skaria J, Katiyar BC, Srivastava TP, Dube B. Myopathy and neuropathy associated with osteomalacia. Acta Neurol Scand 1975; 51:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/31\">",
"      Byrne MF, Razak AR, Leader MB, et al. Disabling osteomalacic myopathy as the only presenting feature of coeliac disease. Eur J Gastroenterol Hepatol 2002; 14:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/32\">",
"      Kozanoglu E, Basaran S, Goncu MK. Proximal myopathy as an unusual presenting feature of celiac disease. Clin Rheumatol 2005; 24:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/33\">",
"      Hadjivassiliou M, Chattopadhyay AK, Gr&uuml;newald RA, et al. Myopathy associated with gluten sensitivity. Muscle Nerve 2007; 35:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/34\">",
"      Berger JR. The neurological complications of bariatric surgery. Arch Neurol 2004; 61:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/35\">",
"      Koffman BM, Greenfield LJ, Ali II, Pirzada NA. Neurologic complications after surgery for obesity. Muscle Nerve 2006; 33:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/36\">",
"      Osteomalacia in a 61-year-old man. Am J Med 1987; 83:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/37\">",
"      Russell JA. Osteomalacic myopathy. Muscle Nerve 1994; 17:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/38\">",
"      Kleopa KA, Kyriacou K, Zamba-Papanicolaou E, Kyriakides T. Reversible inflammatory and vacuolar myopathy with vitamin E deficiency in celiac disease. Muscle Nerve 2005; 31:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/39\">",
"      Ukaonu C, Hill DA, Christensen F. Hypokalemic myopathy in pregnancy caused by clay ingestion. Obstet Gynecol 2003; 102:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/40\">",
"      Rice JE, Faunt JD. Excessive cola consumption as a cause of hypokalaemic myopathy. Intern Med J 2001; 31:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/41\">",
"      Ishikawa S, Kato M, Tokuda T, et al. Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa. Int J Eat Disord 1999; 26:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/42\">",
"      Sharief MK, Robinson SF, Swash M. Hypokalaemic myopathy in alcoholism. Neuromuscul Disord 1997; 7:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/43\">",
"      Taniguchi K, Okino I, Yamamoto N, et al. [Two cases with dropped head syndrome caused by hypokalemic myopathy]. Rinsho Shinkeigaku 2011; 51:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/44\">",
"      Kojima S, Takagi A, Ida M, Shiozawa R. Muscle pathology in polymyalgia rheumatica: histochemical and immunohistochemical study. Jpn J Med 1991; 30:516.",
"     </a>",
"    </li>",
"    <li>",
"     Banker B, Engel A. Other inflammatory myopathies. In: Myology, 3rd, Engel AG, Franzini-Armstrong C.  (Eds), McGraw-Hill, New York 2004. p.1460.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/46\">",
"      Uddhammar A, Rantap&auml;&auml; Dahlqvist S, Hedberg B, Thornell LE. Deltoid muscle in patients with polymyalgia rheumatica. J Rheumatol 1998; 25:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/47\">",
"      Prayson RA. Skeletal muscle vasculitis exclusive of inflammatory myopathic conditions: a clinicopathologic study of 40 patients. Hum Pathol 2002; 33:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/48\">",
"      Panegyres PK, Blumbergs PC, Leong AS, Bourne AJ. Vasculitis of peripheral nerve and skeletal muscle: clinicopathological correlation and immunopathic mechanisms. J Neurol Sci 1990; 100:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/49\">",
"      Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/50\">",
"      Nakamura H, Okada A, Kawakami A, et al. Rheumatoid vasculitis of crural muscles confirmed by muscle biopsy in the absence of inflammatory myopathy: histologic and MRI study. Rheumatol Int 2010; 30:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/51\">",
"      Lacomis D, Giuliani MJ, Wasko MC, Oddis CV. Giant cell arteritis presenting with proximal weakness and skeletal muscle vasculitis. Muscle Nerve 1999; 22:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/52\">",
"      Spuler S, Emslie-Smith A, Engel AG. Amyloid myopathy: an underdiagnosed entity. Ann Neurol 1998; 43:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/53\">",
"      Simmons Z, Specht CS. The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis 2010; 11:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/54\">",
"      Friedman Y, Paul JT, Turley J, et al. Axial myopathy due to primary amyloidosis. Muscle Nerve 2007; 36:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/55\">",
"      Chapin JE, Kornfeld M, Harris A. Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve 2005; 31:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/56\">",
"      Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry 1996; 60:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/57\">",
"      Hull KM, Griffith L, Kuncl RW, Wigley FM. A deceptive case of amyloid myopathy: clinical and magnetic resonance imaging features. Arthritis Rheum 2001; 44:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/58\">",
"      Rubin DI, Hermann RC. Electrophysiologic findings in amyloid myopathy. Muscle Nerve 1999; 22:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/51/14137/abstract/59\">",
"      Yamada M, Tsukagoshi H, Hatakeyama S. Skeletal muscle amyloid deposition in AL- (primary or myeloma-associated), AA- (secondary), and prealbumin-type amyloidosis. J Neurol Sci 1988; 85:223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5158 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.150-851E2265C2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14137=[""].join("\n");
var outline_f13_51_14137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H535106583\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENDOCRINE MYOPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hyperthyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cushing syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hyperaldosteronism with myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hyperparathyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diabetic muscle infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MYOPATHIES ASSOCIATED WITH MALABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Osteomalacic myopathy and celiac sprue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vitamin E deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HYPOKALEMIC MYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MYOPATHY ASSOCIATED WITH CRITICAL ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MYOPATHIES IN RHEUMATIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Skeletal muscle vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Amyloid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H535106583\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1526?source=related_link\">",
"      Diabetic muscle infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=related_link\">",
"      Diagnosis and treatment of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=related_link\">",
"      Genetic factors in the amyloid diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=related_link\">",
"      Medical management of patients after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=related_link\">",
"      Neuromuscular weakness related to critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=related_link\">",
"      Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28133?source=related_link\">",
"      Treatment and prognosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40598?source=related_link\">",
"      Treatment of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_51_14138="Fosphenytoin: Drug information";
var content_f13_51_14138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fosphenytoin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/11/15540?source=see_link\">",
"    see \"Fosphenytoin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23258?source=see_link\">",
"    see \"Fosphenytoin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15795819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cerebyx&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Hydantoin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note: The dose, concentration in solutions, and infusion rates for fosphenytoin are expressed as phenytoin sodium equivalents (PE); fosphenytoin should always be prescribed and dispensed in phenytoin sodium equivalents (PE)",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"     I.V.: Loading dose: 15-20 mg PE/kg administered at 100-150 mg PE/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonemergent loading and maintenance dosing:",
"     </b>",
"     I.V. or I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Loading dose:",
"     </i>",
"     10-20 mg PE/kg (I.V. rate: Infuse more slowly [eg, over 30 minutes]; maximum rate: 150 mg PE/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial daily maintenance dose:",
"     </i>",
"     4-6 mg PE/kg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Substitution for oral phenytoin therapy:",
"     </b>",
"     I.M. or I.V.: May be substituted for oral phenytoin sodium at the same total daily dose; however, Dilantin&reg; capsules are ~90% bioavailable by the oral route; phenytoin, supplied as fosphenytoin, is 100% bioavailable by both the I.M. and I.V. routes; for this reason, plasma phenytoin concentrations may increase when I.M. or I.V. fosphenytoin is substituted for oral phenytoin sodium therapy; in clinical trials, I.M. fosphenytoin was administered as a single daily dose utilizing either 1 or 2 injection sites; some patients may require more frequent dosing",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F174584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23258?source=see_link\">",
"      see \"Fosphenytoin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note: The dose, concentration in solutions, and infusion rates for fosphenytoin are expressed as phenytoin sodium equivalents (PE); fosphenytoin should always be prescribed and dispensed in phenytoin sodium equivalents (PE).",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Infants and Children (unlabeled use):",
"     </i>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     A limited number of clinical studies have been conducted in pediatric patients; based on pharmacokinetic studies, experts recommend the following (Fischer, 2003): Use the pediatric I.V. phenytoin dosing guidelines to dose fosphenytoin using doses in",
"     <b>",
"      PE",
"     </b>",
"     equal to the phenytoin doses (ie, phenytoin 1 mg = fosphenytoin 1 mg",
"     <b>",
"      PE",
"     </b>",
"     ). Further pediatric studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F174569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenytoin clearance is decreased in geriatric patients; lower doses may be required. In addition, older adults may have lower serum albumin which may increase the free fraction and, therefore, pharmacologic response including adverse events. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F174570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No initial dosage adjustment necessary. Free (unbound) phenytoin levels should be monitored closely in patients with renal disease or in those with hypoalbuminemia; furthermore, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance in these patients leading to increase frequency and severity of adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F174571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No initial dosage adjustment necessary. Phenytoin clearance may be substantially reduced in cirrhosis and plasma level monitoring with dose adjustment advisable. Free (unbound) phenytoin levels should be monitored closely in patients with hepatic disease or in those with hypoalbuminemia; furthermore, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance in these patients leading to increased frequency and severity of adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium: 75 mg [50 mg PE]/mL (2 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F174540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: May be administered as a single daily dose using 1-4 injection sites (up to 20 mL per site well tolerated in adults) (Meek, 1999; Pryor, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Rates of infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1-3 mg PE/kg/minute (",
"     <b>",
"      maximum rate: 150 mg PE/minute",
"     </b>",
"     ) (Pellock, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Do not exceed 150 mg PE/minute.",
"     </b>",
"     Slower administration reduces incidence of cardiovascular events (eg, hypotension, arrhythmia) as well as severity of paresthesias and pruritus. For nonemergent situations, may administer loading dose more slowly (eg, over 30 minutes [~33 mg PE/minute for 1000 mg PE]",
"     <b>",
"      or",
"     </b>",
"     50-100 mg PE/minute [Fischer, 2003]).  Highly-sensitive patients (eg, elderly, patients with pre-existing cardiovascular conditions) should receive fosphenytoin more slowly (eg, 25-50 mg PE/minute) (Meek, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F174599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, hetastarch 6% in NS, mannitol 20%, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Lorazepam, phenobarbital.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Fenoldopam, midazolam.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used for the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery; indicated for short-term parenteral administration when other means of phenytoin administration are unavailable, inappropriate, or deemed less advantageous (the safety and effectiveness of fosphenytoin use for more than 5 days has not been systematically evaluated)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cerebyx may be confused with CeleBREX&reg;, CeleXA&reg;, Cerezyme&reg;, Cervarix&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fosphenytoin may be confused with fospropofol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Overdoses have occurred due to confusion between the",
"       <b>",
"        mg per mL concentration",
"       </b>",
"       of fosphenytoin (50 mg phenytoin equivalent (PE)/mL) and",
"       <b>",
"        total drug content per vial",
"       </b>",
"       (either 100 mg PE/2 mL vial or 500 mg PE/10 mL vial). ISMP recommends that the total drug content per container is identified instead of the concentration in mg per mL to avoid confusion and potential overdoses. Additionally, since most errors have occurred with overdoses in children, ISMP recommends that pediatric hospitals consider stocking only the 2 mL vial.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The more important adverse clinical events caused by the I.V. use of fosphenytoin or phenytoin are cardiovascular collapse and/or central nervous system depression. Hypotension can occur when either drug is administered rapidly by the I.V. route.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The adverse clinical events most commonly observed with the use of fosphenytoin in clinical trials were nystagmus, dizziness, pruritus, paresthesia, headache, somnolence, and ataxia. Paresthesia and pruritus were seen more often following fosphenytoin (versus phenytoin) administration and occurred more often with I.V. fosphenytoin than with I.M. administration. These events were dose and rate related (adult doses &ge;15 mg/kg at a rate of 150 mg PE/minute) and occurred in up to 64% of patients. These sensations, generally described as itching, burning, or tingling are usually not at the infusion site. The location of the discomfort varied with the groin mentioned most frequently. The paresthesia and pruritus were transient events that occurred within several minutes of the start of infusion and generally resolved within 10 minutes after completion of infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Transient pruritus, tinnitus, nystagmus, somnolence, and ataxia occurred 2-3 times more often at adult doses &ge;15 mg/kg and rates &ge;150 mg PE/minute.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Also refer to phenytoin monograph for additional adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V. and I.M. administration (as reported in clinical trials):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Facial edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Chills, fever, intracranial hypertension, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperreflexia, myasthenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V. administration",
"     </b>",
"     (maximum dose/rate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Paresthesia (4% to 64%), nystagmus (44%), dizziness (31%), somnolence (20%), ataxia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dermatologic: Pruritus (49% to 64%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cardiovascular: Hypotension (7%), vasodilation (6%), tachycardia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Stupor (7%), extrapyramidal syndrome (4%), incoordination (4%), agitation (3%), tremor (3%), brain edema (2%), headache (2%), hypoesthesia (2%), vertigo (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Nausea (9%), tongue disorder (4%), xerostomia (4%), taste perversion (3%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Pelvic pain (4%), back pain (2%), dysarthria (2%), weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ocular: Diplopia (3%), amblyopia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Otic: Tinnitus (9%), deafness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.M. administration",
"     </b>",
"     (substitute for oral phenytoin):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Nystagmus (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Tremor (10%), headache (9%), ataxia (8%), incoordination (8%), somnolence (7%), dizziness (5%), paresthesia (4%), reflexes decreased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dermatologic: Bruising (7%), pruritus (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5%), vomiting (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V. and I.M. administration:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Acidosis, acute hepatic failure, acute hepatotoxicity, alkalosis, akathisia, amnesia, anemia, anorexia, aphasia, apnea, arthralgia, asthma, atrial flutter, Babinski sign positive, bundle branch block, cachexia, cardiac arrest, cardiomegaly, cerebral hemorrhage, cerebral infarct, CHF, circumoral paresthesia, CNS depression, cyanosis,  dehydration, diabetes insipidus, dyskinesia, dysphagia, dyspnea, edema, emotional lability, encephalopathy, epistaxis, extrapyramidal symptoms, GI hemorrhage, hemiplegia, hemoptysis, hostility, hyperacusis, hyperesthesia, hyper-/hypokinesia, hyperkalemia, hyperventilation, hypochromic anemia, hypophosphatemia, hypotonia, hypoxia, ileus, injection site (edema, hemorrhage, inflammation), ketosis, leg cramps, leukocytosis, leukopenia, LFTs abnormal, malaise, migraine, myalgia, mydriasis, myopathy, neurosis, orthostatic hypotension, palpitation, paralysis, parosmia, petechia, photophobia, photosensitivity reaction, psychosis, pulmonary embolus, QT interval prolongation, rash (maculopapular or pustular), renal failure, sinus bradycardia, shock, subdural hematoma, syncope, Stevens-Johnson syndrome, tenesmus, thrombocytopenia, thrombophlebitis, tongue edema, toxic epidermal necrolysis, urticaria, ventricular extrasystoles, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F174543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenytoin, other hydantoins, or any component of the formulation; patients with sinus bradycardia, sinoatrial block, second- and third-degree AV block, or Adams-Stokes syndrome; occurrence of rash during treatment (should not be resumed if rash is exfoliative, purpuric, or bullous); treatment of absence seizures; concurrent use of delavirdine (due to loss of virologic response and possible resistance to delavirdine or other non-nucleoside reverse transcriptase inhibitors [NNRTIs])",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: A spectrum of hematologic effects have been reported with use (eg, neutropenia, leukopenia, thrombocytopenia, pancytopenia, and anemias); patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: Fosphenytoin administration should not exceed 150 mg phenytoin equivalents (PE)/minute in adult patients.",
"     </b>",
"     Hypotension and severe cardiac arrhythmias (eg, heart block, ventricular tachycardia, ventricular fibrillation) may occur with rapid administration; adverse cardiac events have been reported at or below the recommended infusion rate. In the treatment of status epilepticus, the rate of administration is 150 mg PE/minute. In a nonemergent situation, administer more slowly or use oral phenytoin.  Cardiac monitoring is necessary during and after administration of intravenous fosphenytoin; reduction in rate of administration or discontinuation of infusion may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Severe reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndromes, although rarely reported, have resulted in fatalities; drug should be discontinued if there are any signs of rash and patient should be evaluated for signs and symptoms of drug reaction with eosinophilia and systemic symptoms (DRESS). Data suggests a genetic susceptibility for serious skin reactions in patients of Asian descent (see \"Special populations\" below).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity syndrome: Acute hepatotoxicity associated with a hypersensitivity syndrome characterized by fever, skin eruptions, and lymphadenopathy has been reported to occur within the first 2 months of treatment; discontinue if skin rash or lymphadenopathy occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Local toxicity: The \"purple glove syndrome\" (ie, discoloration with edema and pain of distal limb) may occur following peripheral I.V. administration of fosphenytoin. This syndrome may or may not be associated with drug extravasation. Symptoms may resolve spontaneously; however, skin necrosis and limb ischemia may occur. In general, fosphenytoin has significantly less venous irritation and phlebitis compared with an equimolar dose of phenytoin (Jamerson, 1994).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sensory disturbances: Severe burning or itching, and/or paresthesias, mostly perineal, may occur upon administration, usually at the maximum administration rate and last from minutes to hours; occurrence and intensity may be lessened by slowing or temporarily stopping the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with hypotension and/or severe myocardial insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus. Phenytoin may inhibit insulin release; may increase serum glucose in patients with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fever: Use with caution in patients with fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoalbuminemia: Use with caution in patients with any condition associated with low serum albumin levels, which will increase the free fraction of phenytoin in the serum and, therefore, the pharmacologic response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypothyroidism: Use with caution in patients with hypothyroidism; phenytoin may alter thyroid hormone serum concentrations (with chronic administration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; also consider the phosphate load of fosphenytoin (0.0037 mmol phosphate/mg PE fosphenytoin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asian ancestry: Asian patients with the variant",
"     <i>",
"      HLA-B*1502",
"     </i>",
"     may be at an increased risk of developing Stevens-Johnson syndrome and/or TEN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenytoin sodium equivalent (PE):",
"     <b>",
"      Doses of fosphenytoin are always expressed as their phenytoin sodium equivalent (PE). Thus, 1 mg PE is equivalent to 1 mg phenytoin sodium. Do not change the recommended doses when substituting fosphenytoin for phenytoin or vice versa as they are not equivalent on a mg to mg basis.",
"     </b>",
"     Dosing errors have also occurred due to misinterpretation of vial concentrations resulting in two- or tenfold overdoses (some fatal); ensure correct volume of fosphenytoin is withdrawn from vial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serum concentrations: Sedation, confusional states, or cerebellar dysfunction (loss of motor coordination) may occur at higher total serum concentrations or when the free fraction of phenytoin is increased at lower total serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F174587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (strong), CYP2C19 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Anticonvulsants (Hydantoin) may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Fosphenytoin. Alcohol (Ethyl) may decrease the serum concentration of Fosphenytoin. This may be particularly applicable with chronic, heavy alcohol consumption. Alcohol (Ethyl) may increase the serum concentration of Fosphenytoin. This may be particularly applicable with acute, heavy alcohol consumption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Fosphenytoin may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: May increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     ALPRAZolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: Fosphenytoin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Fosphenytoin may decrease the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May increase the serum concentration of Fosphenytoin. Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capecitabine: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Fosphenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin. Possibly by competitive inhibition at sites of metabolism. Fosphenytoin may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CeFAZolin: May decrease the protein binding of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Anticonvulsants (Hydantoin). Anticonvulsants (Hydantoin) may decrease the serum concentration of Chloramphenicol. Increased chloramphenicol concentrations have also been seen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Cimetidine may increase the serum concentration of Anticonvulsants (Hydantoin). Management: Consider using an alternative H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist to avoid this interaction. Monitor for toxic effects of hydantoin anticonvulsants if cimetidine is initiated/dose increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Fosphenytoin may decrease the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Fosphenytoin-Phenytoin may decrease the serum concentration of Cobicistat.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Fosphenytoin may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Fosphenytoin may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Fosphenytoin may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Fosphenytoin may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Fosphenytoin may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May decrease the serum concentration of Fosphenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Fosphenytoin may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Fosphenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible.  Phenytoin dose adjustment will likely be necessary when starting and/or stopping concurrent disulfiram.  Monitor phenytoin response and concentrations closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Fosphenytoin may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Fosphenytoin-Phenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: May enhance the CNS depressant effect of Fosphenytoin. Ethosuximide may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Fosphenytoin may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Fosphenytoin may decrease the serum concentration of Etoposide Phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Fosphenytoin may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Felbamate. Management: Decreased phenytoin dose will likely be needed when adding felbamate; some reports suggest an empiric 20% decrease in phenytoin dose. Additional reductions may be needed if felbamate dose is increased or as otherwise guided by monitoring.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floxuridine: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flunarizine: Fosphenytoin may decrease the serum concentration of Flunarizine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic Acid: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halothane: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Fosphenytoin may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Fosphenytoin may decrease the serum concentration of Irinotecan.  Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenytoin, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May increase the serum concentration of Fosphenytoin. Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lacosamide: Fosphenytoin may decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Fosphenytoin may decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Fosphenytoin may diminish the therapeutic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levomefolate: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Fosphenytoin may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Fosphenytoin may diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Fosphenytoin may decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Fosphenytoin.  Management: The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: Fosphenytoin may decrease the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Fosphenytoin may decrease the serum concentration of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Fosphenytoin may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: Fosphenytoin may decrease the serum concentration of MethylPREDNISolone.  Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during phenytoin treatment, and increased methylprednisolone effects following phenytoin discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): Fosphenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: Fosphenytoin may decrease the serum concentration of Metyrapone. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Fosphenytoin may decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Fosphenytoin-Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Fosphenytoin may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: Fosphenytoin-Phenytoin may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with phenytoin/fosphenytoin.  Patients receiving this combination should be followed closely for response, especially with any changes to phenytoin/fosphenytoin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): Fosphenytoin may decrease the serum concentration of PrednisoLONE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Fosphenytoin may decrease serum concentrations of the active metabolite(s) of PredniSONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Fosphenytoin may increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Fosphenytoin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dexlansoprazole; Esomeprazole; Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QUEtiapine: Fosphenytoin may decrease the serum concentration of QUEtiapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Fosphenytoin may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Fosphenytoin may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Fosphenytoin may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Fosphenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: Fosphenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Fosphenytoin may decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Fosphenytoin may decrease the serum concentration of Sirolimus.  Management: Monitor for decreased sirolimus concentrations if fosphenytoin/phenytoin is initiated/dose increased. Monitor for increased sirolimus concentrations with phenytoin discontinuation/dose decrease. Sirolimus dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Fosphenytoin may decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Fosphenytoin may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Fosphenytoin. Telaprevir may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Fosphenytoin may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree).  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as phenytoin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Fosphenytoin may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May decrease the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Fosphenytoin may decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticlopidine: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Fosphenytoin may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Fosphenytoin may decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Fosphenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Fosphenytoin may increase the metabolism of Valproic Acid. A hepatotoxic metabolite of valproic acid may result. Valproic Acid may decrease the serum concentration of Fosphenytoin. Continued therapy usually yields a normalization (or slight increase) of serum phenytoin concentrations.  Free phenytoin concentrations, however, tend to remain relatively stable (possibly increased with continued therapy).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vecuronium: Fosphenytoin may diminish the therapeutic effect of Vecuronium. Fosphenytoin may enhance the therapeutic effect of Vecuronium. Fosphenytoin may decrease the serum concentration of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vigabatrin: May decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Fosphenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fosphenytoin may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin.  Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zonisamide: Fosphenytoin may decrease the serum concentration of Zonisamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F174559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ethanol:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute use: Avoid or limit ethanol (inhibits metabolism of phenytoin). Ethanol may also increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic use: Avoid or limit ethanol (stimulates metabolism of phenytoin).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosphenytoin is the prodrug of phenytoin. Refer to Phenytoin monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F174547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosphenytoin is the prodrug of phenytoin. It is not known if fosphenytoin is excreted in breast milk prior to conversion to phenytoin. Refer to Phenytoin monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F174548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provides phosphate 0.0037 mmol/mg PE fosphenytoin",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fosphenytoin Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg PE/2 mL (2 mL): $1.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg PE/10 mL (10 mL): $8.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F174533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous blood pressure, ECG, and respiratory function monitoring with loading dose and for 10-20 minutes following infusion; vital signs, CBC, hepatic function tests, plasma phenytoin concentration monitoring (plasma concentrations should not be measured until conversion to phenytoin is complete, ~2 hours after an I.V. infusion or ~4 hours after an I.M. injection).",
"     <b>",
"      Note:",
"     </b>",
"     If available, free (unbound) phenytoin concentrations should be obtained in patients with renal impairment and/or hypoalbuminemia; if free phenytoin concentrations are unavailable, the adjusted total concentration may be determined based upon equations in adult patients. Trough concentrations are generally recommended for routine monitoring.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F174536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 10-20 mcg/mL (SI: 40-79 micromole/L); toxicity is measured clinically, and some patients require levels outside the suggested therapeutic range",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;30 mcg/mL (SI: 120 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lethal",
"     </b>",
"     : &gt;100 mcg/mL (SI: &gt;400 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Manifestations of toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nystagmus: 20 mcg/mL (SI: 79 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ataxia: 30 mcg/mL (SI: 118.9 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Decreased mental status: 40 mcg/mL (SI: 159 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coma: 50 mcg/mL (SI: 200 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak serum phenytoin level after a 375 mg I.M. fosphenytoin dose in healthy males: 5.7 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak serum fosphenytoin levels and phenytoin levels after a 1.2 g infusion (I.V.) in healthy subjects over 30 minutes were 129 mcg/mL and 17.2 mcg/mL, respectively",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cerebyx (KP);",
"     </li>",
"     <li>",
"      Cereneu (TH);",
"     </li>",
"     <li>",
"      Fosolin (IN);",
"     </li>",
"     <li>",
"      Pro-Epanutin (AT, AU, DK, FI, GB, GR, IE, NL, NO, SE);",
"     </li>",
"     <li>",
"      ProDilantin (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diphosphate ester salt of phenytoin which acts as a water soluble prodrug of phenytoin; after administration, plasma esterases convert fosphenytoin to phosphate, formaldehyde, and phenytoin as the active moiety; phenytoin works by stabilizing neuronal membranes and decreasing seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also refer to Phenytoin monograph for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Fosphenytoin: V",
"     <sub>",
"      d",
"     </sub>",
"     : 4.3-10.8 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Fosphenytoin: 95% to 99% to albumin; can displace phenytoin and increase free fraction (up to 30% unbound) during the period required for conversion of fosphenytoin to phenytoin.",
"     <b>",
"      Note:",
"     </b>",
"     In patients with renal and/or hepatic impairment or hypoalbuminemia, the fraction of unbound phenytoin may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Fosphenytoin is rapidly converted via hydrolysis to phenytoin; phenytoin is metabolized in the liver and forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: I.M.: Fosphenytoin: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fosphenytoin: Conversion half-life: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenytoin: Variable (mean: 12-29 hours); kinetics of phenytoin are saturable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Conversion to phenytoin: Following I.V. administration (maximum rate of administration): 15 minutes; following I.M. administration, peak phenytoin levels are reached in 3 hours; therapeutic phenytoin concentrations may be achieved as early as 5-20 minutes following I.M. (gluteal) administration (Pryor, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Phenytoin: Urine (as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bebin M and Bleck TP, &ldquo;New Anticonvulsant Drugs. Focus on Flunarizine, Fosphenytoin, Midazolam, and Stiripentol,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1994, 48(2):153-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/7527321/pubmed\" id=\"7527321\" target=\"_blank\">",
"        7527321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boucher BA, &ldquo;Fosphenytoin: A Novel Phenytoin Prodrug,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1996, 16(5):777-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/8888074/pubmed\" id=\"8888074\" target=\"_blank\">",
"        8888074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boucher BA, Feler CA, Dean JC, et al, &ldquo;The Safety, Tolerability, and Pharmacokinetics of Fosphenytoin After Intramuscular and Intravenous Administration in Neurosurgery Patients,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1996, 16(4):638-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/8840370/pubmed\" id=\"8840370\" target=\"_blank\">",
"        8840370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman MG, Smith M, and Hirsch NP, &ldquo;Status Epilepticus,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2001, 56(7):648-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/11437765/pubmed\" id=\"11437765\" target=\"_blank\">",
"        11437765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer JH, Cwik MS, Luer MS, et al, &ldquo;Stability of Fosphenytoin Sodium With Intravenous Solutions in Glass Bottles, Polyvinyl Chloride Bags, and Polypropylene Syringes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(5):553-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/9161647/pubmed\" id=\"9161647\" target=\"_blank\">",
"        9161647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jamerson BD, Dukes GE, Brouwer KL, et al, &ldquo;Venous Irritation Related to Intravenous Administration of Phenytoin Versus Fosphenytoin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1994, 14(1):47-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/8159601/pubmed\" id=\"8159601\" target=\"_blank\">",
"        8159601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalviainen R, &ldquo;Status Epilepticus Treatment Guidelines,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(Suppl 8):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/18330014/pubmed\" id=\"18330014\" target=\"_blank\">",
"        18330014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leppik IE, Boucher R, Wilder BJ, et al, &ldquo;Phenytoin Prodrug: Preclinical and Clinical Studies,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1989, 30(Suppl 2):22-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manno EM, &ldquo;New Management Strategies in the Treatment of Status Epilepticus,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2003, 78(4):508-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/12683704/pubmed\" id=\"12683704\" target=\"_blank\">",
"        12683704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meek PD, Davis SN, Collins DM, et al, \"Guidelines for Nonemergency Use of Parenteral Phenytoin Products: Proceedings of an Expert Panel Consensus Process. Panel on Nonemergency Use of Parenteral Phenytoin Products,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1999, 159(22):2639-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/10597754/pubmed\" id=\"10597754\" target=\"_blank\">",
"        10597754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meierkord H, Boon P, Engelsen B, et al, &ldquo;EFNS Guideline on the Management of Status Epilepticus in Adults,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2010,17(3):348-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/20050893/pubmed\" id=\"20050893\" target=\"_blank\">",
"        20050893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pellock JM, &ldquo;Fosphenytoin Use in Children,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1996, 46(6 Suppl 1):14-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pryor FM, Gidal B, Ramsay RE, et al, &ldquo;Fosphenytoin: Pharmacokinetics and Tolerance of Intramuscular Loading Doses,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2001, 42(2):245:50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/11240597/pubmed\" id=\"11240597\" target=\"_blank\">",
"        11240597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verrotti A, Scardapane A, Manco R, et al, &ldquo;Antiepileptic Drugs and Thyroid Function,&rdquo;",
"      <i>",
"       J Ped Endocrinol Metab",
"      </i>",
"      , 2008, 21(5):401-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/18655520/pubmed\" id=\"18655520\" target=\"_blank\">",
"        18655520",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilder BJ, Campbell K, Ramsay RE, et al, &ldquo;Safety and Tolerance of Multiple Doses of Intramuscular Fosphenytoin Substituted for Oral Phenytoin in Epilepsy or Neurosurgery,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 1996, 53(8):764-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/51/14138/abstract-text/8759983/pubmed\" id=\"8759983\" target=\"_blank\">",
"        8759983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8480 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-335F5A8ACC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14138=[""].join("\n");
var outline_f13_51_14138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795819\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174565\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174593\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174568\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174584\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174569\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174570\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174571\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174535\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174519\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174540\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174599\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174539\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174602\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174591\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174543\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174523\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174587\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174528\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174559\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174531\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174546\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174575\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174547\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174548\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323162\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174533\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174536\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038644\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174522\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174542\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8480\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8480|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/11/15540?source=related_link\">",
"      Fosphenytoin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23258?source=related_link\">",
"      Fosphenytoin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_51_14139="Treatable causes of myocarditis";
var content_f13_51_14139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Myocarditides subject to specific therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Cytomegalovirus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyme carditis (Borrelia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycoplasma infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psittacosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Legionnaire's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella/Shigella infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptospirosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsial infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coccidioidomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptococcosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus myocarditis (?)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14139=[""].join("\n");
var outline_f13_51_14139=null;
var title_f13_51_14140="Parasitic infections associated with nodular lesions";
var content_f13_51_14140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parasites causing nodular lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coenurosis",
"       </td>",
"       <td>",
"        Usually single, subcutaneous nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cysticercosis",
"       </td>",
"       <td>",
"        Painless, rubbery nodules; often multiple",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dirofilariasis",
"       </td>",
"       <td>",
"        Subcutaneous nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dracunculiasis",
"       </td>",
"       <td>",
"        Papular or nodular lesion breaks down to discharge the worm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcosis",
"       </td>",
"       <td>",
"        Soft, subcutaneous cysts of variable sizes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fascioliasis",
"       </td>",
"       <td>",
"        Painful or itchy subcutaneous nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Filariasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Loaisis",
"       </td>",
"       <td class=\"sublist_other\">",
"        Painful or itchy swellings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Onchocerciasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        Subcutaneous nodules; papular, itchy rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Wuchereria bancrofti",
"       </td>",
"       <td class=\"sublist_other\">",
"        Recurrent lymphangitis; scrotal mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gnathostomiasis",
"       </td>",
"       <td>",
"        Edematous, recurrent, migratory subcutaneous swellings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paragonimiasis",
"       </td>",
"       <td>",
"        Subcutaneous nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcocystis",
"       </td>",
"       <td>",
"        Subcutaneous nodules, eosinophilic myositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schistosomiasis",
"       </td>",
"       <td>",
"        Verrucous, vegetating lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sparganosis",
"       </td>",
"       <td>",
"        Edematous, painful migratory swellings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visceral larva migrans",
"       </td>",
"       <td>",
"        Tender nodular rash",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14140=[""].join("\n");
var outline_f13_51_14140=null;
var title_f13_51_14141="LV function stroke risk in AF";
var content_f13_51_14141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Significant left ventricular dysfunction predicts stroke in AF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 285px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a prospective study of 1066 patients entered into three clinical trials evaluating the role of anticoagulation in nonvalvular AF (BAATAF, SPINAF, and SPAF) the incidence of a stroke was 9.3 percent per year in patients with moderate to severe left ventricular dysfunction compared to 4.4 percent per year in those with normal or mildly abnormal left ventricular function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Atrial Fibrillation Investigators, Arch Intern Med 1998; 158:1316.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14141=[""].join("\n");
var outline_f13_51_14141=null;
var title_f13_51_14142="Effect on exercise capacity";
var content_f13_51_14142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of pulmonary rehabilitation on exercise capacity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 471px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of respiratory rehabilitation on functional exercise capacity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lacasse Y, Wong E, Guyatt GH, et al. Lancet 1996; 348:1115.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14142=[""].join("\n");
var outline_f13_51_14142=null;
var title_f13_51_14143="Skeletal lead lines";
var content_f13_51_14143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skeletal lead lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-bone radiographs demonstrating lead lines (increased opacity of the proximal tibial and fibular metaphyses, arrows) in a child with chronic lead toxicity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Hurwitz, MD and Dean A Lee, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_51_14143=[""].join("\n");
var outline_f13_51_14143=null;
